U.S. patent application number 16/825757 was filed with the patent office on 2020-09-10 for methods of expanding and assessing b cells and using expanded b cells to treat disease.
This patent application is currently assigned to DUKE UNIVERSITY. The applicant listed for this patent is DUKE UNIVERSITY. Invention is credited to Evgueni Kountikov, Tomomitsu Miyagaki, Jonathan C. Poe, Thomas F. Tedder, Ayumi Yoshizaki.
Application Number | 20200283727 16/825757 |
Document ID | / |
Family ID | 1000004856438 |
Filed Date | 2020-09-10 |
United States Patent
Application |
20200283727 |
Kind Code |
A1 |
Tedder; Thomas F. ; et
al. |
September 10, 2020 |
METHODS OF EXPANDING AND ASSESSING B CELLS AND USING EXPANDED B
CELLS TO TREAT DISEASE
Abstract
Provided herein are methods of expanding B cells, and in
particularly B10 cells capable of producing IL-10, ex vivo. The
methods include incubation of harvested B cells in the presence of
IL-21. Compositions comprising the ex vivo expanded B cells and
methods of using the expanded B cell-containing compositions to
treat diseases or conditions are also provided. Methods of
assessing B10 cell function in a subject are also provided.
Inventors: |
Tedder; Thomas F.; (Durham,
NC) ; Yoshizaki; Ayumi; (Durham, NC) ;
Miyagaki; Tomomitsu; (Durham, NC) ; Kountikov;
Evgueni; (Durham, NC) ; Poe; Jonathan C.;
(Durham, NC) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
DUKE UNIVERSITY |
Durham |
NC |
US |
|
|
Assignee: |
DUKE UNIVERSITY
Durham
NC
|
Family ID: |
1000004856438 |
Appl. No.: |
16/825757 |
Filed: |
March 20, 2020 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
16000604 |
Jun 5, 2018 |
10611999 |
|
|
16825757 |
|
|
|
|
13795889 |
Mar 12, 2013 |
10017739 |
|
|
16000604 |
|
|
|
|
61697663 |
Sep 6, 2012 |
|
|
|
61707256 |
Sep 28, 2012 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C12N 2501/24 20130101;
C12N 2501/2306 20130101; A61K 35/17 20130101; C12N 2501/599
20130101; C12N 2501/2321 20130101; C12N 2501/2312 20130101; C12N
2501/2304 20130101; C12N 2501/52 20130101; C12N 2501/15 20130101;
C12N 2501/231 20130101; C12N 5/0635 20130101 |
International
Class: |
C12N 5/0781 20060101
C12N005/0781; A61K 35/17 20060101 A61K035/17 |
Goverment Interests
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH
[0002] This invention was made with United States government
support awarded by the National Institutes of Health grant number
A1057157 and U19 A156363. The United States may have certain rights
in this invention.
Claims
1.-21. (canceled)
22. (canceled)
23. (canceled)
24. A method of treating a subject having an autoimmune disorder
comprising administering a therapeutically effective amount of a
composition comprising B10 cells cultured in vitro with IL-21,
wherein the B10 cells are more than 85% of the total B cells in the
composition and wherein said B10 cells are capable of producing
IL-10 to a subject in need of treatment for an autoimmune
disorder.
25. The method of claim 24, wherein the autoimmune disease is
selected from multiple sclerosis, lupus, arthritis, inflammatory
bowel disease and scleroderma.
26. The method of claim 24, wherein the autoimmune disease is
selected from allergic contact dermatitis, allergic reactions to
drugs, alopecia areata, ankylosing spondylitis, antiphospholipid
syndrome, autoimmune Addison's disease, autoimmune diseases of the
adrenal gland, autoimmune hemolytic anemia, autoimmune hepatitis,
autoimmune oophoritis and orchitis, autoimmune thrombocytopenia,
Behcet's disease, bullous pemphigoid and associated skin diseases,
cardiomyopathy, Celiac disease, Celiac sprue-dermatitis, chronic
fatigue immune dysfunction syndrome (CFIDS), chronic inflammatory
demyelinating polyneuropathy, Churg-Strauss syndrome, cicatrical
pemphigoid, CREST syndrome, cold agglutinin disease, Crohn's
disease, cutaneous necrotizing venulitis, discoid lupus, erythema
multiforme, essential mixed cryoglobulinemia,
fibromyalgia-fibromyositis, glomerulonephritis, Graves' disease,
Guillain-Barre, Hashimoto's thyroiditis, idiopathic pulmonary
fibrosis, idiopathic/autoimmune thrombocytopenia purpura (ITP),
immunologic lung disease, immunologic renal disease, IgA
neuropathy, juvenile arthritis, lichen planus, Meniere's disease,
mixed connective tissue disease, type 1 or immune-mediated diabetes
mellitus, myasthenia gravis, pemphigus-related disorders (e.g.,
pemphigus vulgaris), pernicious anemia, polyarteritis nodosa,
polychrondritis, polyglandular syndromes, polymyalgia rheumatica,
polymyositis and dermatomyositis, primary agammaglobulinemia,
primary biliary cirrhosis, psoriasis, psoriatic arthritis,
Raynauld's phenomenon, Reiter's syndrome, Rheumatoid arthritis,
rheumatic fever, sarcoidosis, Sjogren's syndrome, stiff-man
syndrome, spondyloarthropathies, systemic lupus erythematosis
(SLE), lupus erythematosus, systemic vasculitis, takayasu
arteritis, temporal arteristis/giant cell arteritis,
thrombocytopenia, thyroiditis, ulcerative colitis, uveitis,
vasculitides such as dermatitis herpetiformis vasculitis, vitiligo,
and Wegener's granulomatosis.
27. A method of treating a subject to prevent or treat organ,
tissue or cell transplant rejection or associated chronic graft
versus host disease or treating a subject receiving recombinant,
therapeutic or xenogeneic protein(s) comprising administering a
therapeutically effective amount of a composition comprising B10
cells cultured in vitro with IL-21, wherein the B10 cells are more
than 85% of the total B cells in the composition and wherein said
B10 cells are capable of producing IL-10 to a subject in need of
treatment for transplant rejection, graft versus host disease or
other disorder associated with receipt of a transplant or protein
treatment.
28. A method of treating a subject having an allergic disorder or
inflammatory disorder comprising administering a therapeutically
effective amount of a composition comprising B10 cells cultured in
vitro with IL-21, wherein the B10 cells are more than 85% of the
total B cells in the composition and wherein said B10 cells are
capable of producing IL 10 to a subject in need of treatment for
allergies or for inflammation.
29. (canceled)
30. The method of claim 28, wherein the inflammatory disorder is
selected from asthma, encephilitis, inflammatory bowel disease,
chronic obstructive pulmonary disease (COPD), allergic disorders,
septic shock, pulmonary fibrosis, undifferentitated
spondyloarthropathy, undifferentiated arthropathy, arthritis,
inflammatory osteolysis, and chronic inflammation resulting from
chronic viral or bacterial infections.
31. (canceled)
32. The method of claim 24, wherein the composition comprises
autologous B10 cells.
33. (canceled)
34. The method of claim 24, wherein the composition is administered
after the onset of symptoms in the subject.
35.-49. (canceled)
50. The method of claim 24, wherein the composition comprises
between 10.sup.6 and 10.sup.10 B10 cells.
51. The method of claim 24, wherein the B10 cells were cultured in
vitro with a CD40 agonist.
52. The method of claim 51, wherein the CD40 agonist is CD154, a
fragment of CD154, or antibody, aptamer or polypeptide, or fragment
thereof reactive with CD40.
53. The method of claim 24, wherein the B10 cells were cultured in
vitro with a B cells survival promoter.
54. The method of claim 53, wherein the B cell survival promoter is
selected from at least one of feeder cells, BAFF (BLyS), BAFF
fragments, APRIL, CD22 ligand, CD22 monoclonal antibody, or
fragments thereof.
55. The method of claim 24, wherein the B10 cells were cultured on
feeder cells expressing a CD40 agonist and a B cell survival
promoter.
56. The method of claim 55, wherein the feeder cells are
fibroblast, endothelial cells, epithelial cells, keratinocytes,
melanocytes, or other mesenchymal or stromal cells.
57. The method of claim 24, wherein the B10 cells were cultured in
vitro with IL-4.
58. The method of claim 28, wherein the composition comprises
autologous B10 cells.
59. The method of claim 28, wherein the B10 cells were cultured in
vitro with a CD40 agonist.
60. The method of claim 28, wherein the B10 cells were cultured in
vitro with a B cells survival promoter.
61. The method of claim 28, wherein the B10 cells were cultured in
vitro with IL-4
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This patent application is a divisional of U.S. patent
application Ser. No. 16/000,604, filed Jun. 5, 2018, and issued as
U.S. Pat. No. 10,611,999 on Apr. 7, 2020, which claims the benefit
of priority of U.S. patent application Ser. No. 13/795,889, filed
Mar. 12, 2013, and issued as U.S. Pat. No. 10,017,739 on Jul. 10,
2018, which claims the benefit of priority of U.S. Provisional
Patent Application No. 61/697,663, filed Sep. 6, 2012 and U.S.
Provisional Patent Application No. 61/707,256, filed Sep. 28, 2012,
all of which are incorporated herein by reference in their
entireties.
INTRODUCTION
[0003] It is well-known that B cells regulate immune responses by
producing antigen-specific antibody. However, specific B cell
subsets can also negatively regulate immune responses, validating
the existence of regulatory B cells. Human and mouse regulatory B
cells (B10 cells) with the ability to express the inhibitory
cytokine interleukin-10 (IL-10) have been identified. Although
rare, B10 cells are potent negative regulators of antigen-specific
inflammation and T cell-dependent autoimmune disease in mice. B10
cell IL-10 production regulates antigen-specific immune responses
in vivo without inducing systemic immunosuppression. B10 cells may
thereby be useful in regulating or controlling inflammation or
autoimmune diseases.
SUMMARY
[0004] Provided herein are methods of expanding B cells ex vivo,
compositions comprising expanded B cells and methods of using the
expanded B cell compositions for assessing or screening for a
disease state or condition and for treating diseases as described
herein. Methods of expanding B10 cells capable of producing IL-10
ex vivo by culturing or incubating B cells harvested and isolated
from a subject with IL-21 are provided herein. The resultant
expanded polyclonal B cells can be collected or isolated from the
culture and may be further harvested to select for B10 cells.
[0005] The methods of expanding B cells ex vivo include culturing B
cells harvested from a subject on feeder cells expressing a CD40
agonist and a B cell survival promoter such as BAFF in the presence
of IL-4 and then culturing the resultant cells on feeder cells
expressing a CD40 agonist and a B cell survival promoter such as
BAFF in the presence of IL-21 prior to collecting or isolating the
expanded polyclonal B cells. The expanded polyclonal B cells may
also be further selected. For example, the expanded polyclonal B
cells may be further selected to isolate B10 cells.
[0006] Compositions comprising the expanded polyclonal B cells and
B10 cells produced by the methods described herein are also
provided. The composition comprising the expanded polyclonal B
cells produced by the methods described herein may be further
selected to produce a composition comprising B10 cells. The
compositions of expanded polyclonal B cells and/or B10 cells may be
used in a variety of methods to treat various diseases or
conditions. Pharmaceutical compositions including the expanded
polyclonal B cell and B10 cell compositions described herein are
also provided.
[0007] Methods of treating a subject having an autoimmune disease,
an allergic disorder, an inflammatory disorder or immunodeficiency
are provided. The methods include administering a therapeutically
effective amount of the compositions comprising expanded polyclonal
B cells or B10 cells described herein to a subject in need of
treatment for an autoimmune disease, an allergic disorder, an
inflammatory disorder or an immunodeficiency.
[0008] Methods of treating a subject to prevent or treat organ,
tissue or cell transplant rejection or associated graft versus host
disease are also provided. The methods include administering a
therapeutically effective amount of the compositions including the
B cells and/or B10 cells described herein to a subject in need of
treatment for transplant rejection or graft versus host
disease.
[0009] Methods of treating a subject receiving recombinant,
therapeutic or xenogeneic protein(s) are also provided. The methods
include administering a therapeutically effective amount of the
compositions including the B cells and/or B10 cells disclosed
herein to a subject in need of treatment for a genetic,
transplantation, allergy, inflammation, or autoimmune disorder.
[0010] Methods of assessing B10 cell function in a subject are also
provided. In these methods, the B cells are harvested from a sample
from the subject and cultured in the presence of IL-21 for at least
24 hours. The B cells are then tested to determine whether the
cells are capable of producing IL-10 and/or the amount of IL-10
produced or the percentage of cells capable of producing IL-10 in
the culture as compared to a control having normal B cell function
is determined. B cells expressing IL-10 are B10 cells. The B cells
may be cultured on feeder cells expressing a CD40 agonist and a B
cell survival promoter such as BAFF in the presence of IL-4 and
subsequently in the presence of IL-21 prior to assessment of the
ability of the cells to produce IL-10.
[0011] The methods of assessing B10 cell function provided herein
may be used to diagnose an autoimmune or inflammatory disease or
may be used to assess the stage of a disease or condition in the
subject.
BRIEF DESCRIPTION OF THE DRAWINGS
[0012] FIG. 1 is a set of data which demonstrate that IL-21 induces
regulatory B10 cell function. (A) FACS analysis dot plots and
graphs of the data showing that IL-21 induces B10 cell IL-10
production and secretion. Spleen CD19.sup.+ B cells purified from
wild type mice were cultured in medium alone or with the indicated
recombinant cytokines or LPS. To visualize IL-10-competent B cells,
LPS, PMA, ionomycin and monensin (L+PIM) were added to the cultures
5 h before the cells were isolated, stained with CD19 mAb,
permeabilized, stained for cytoplasmic IL-10 expression and
analyzed by flow cytometry. Representative histograms show
IL-10.sup.+ cell frequencies within the indicated gates, with
background staining shown for cells cultured with monensin (Mon.)
alone. Bar graphs indicate mean (.+-.SEM) IL-10.sup.+ B cell
frequencies or culture supernatant fluid IL-10 concentrations at 48
or 72 h from three independent experiments using individual mice.
(B) Dot plots showing that IL-21 induces CD1d.sup.hiCD5.sup.+ B
cell IL-10 production. Purified spleen CD1d.sup.hiCD5.sup.+ or
CD1d.sup.loCD5.sup.- B cells from wild type mice were cultured with
media alone or containing IL-21 for 48 h before IL-10.sup.+ B cell
frequencies were assessed as in (A). (C) Graphs showing that B10
cells express IL-21R. CD19.sup.+ splenocytes purified from wild
type mice were cultured with L+PIM for 5 h before cell surface CD19
and IL-21R, and cytoplasmic IL-10 staining to identify
IL-10-competent B10 cells (dot plot, left panel). Representative
IL-21R expression by IL-10.sup.+ and IL-10.sup.- B cells from wild
type mice is shown in comparison with control B cells from
IL-21R.sup.-/- mice (gray histograms). These results are
representative of three independent experiments using individual
mice. (D) Graphs showing that IL-21R expression is required for B10
cell expansion in vivo following MOG immunization. B10 cell numbers
were assessed in wild type, IL-21R.sup.-/- or CD19.sup.-/- mice 7
days after receiving PBS or MOG.sub.35-55 immunization.
Representative flow cytometry histograms are shown. Bar graphs
indicate mean (.+-.SEM) B10 cell frequencies (>3 mice per
group). Significant differences between sample means are indicated
in (A) and (D); *, p<0.05; **, p<0.01.
[0013] FIG. 2 is a set of data which demonstrate that B10 cells
require IL-10, IL-21R, CD40, and MHC-II expression to regulate EAE
severity. (A) Experimental protocol and resulting disease severity
in various mice after administration of MOG.sub.35-55. One day
before CD19.sup.-/- or wild type (WT) mice were immunized with
MOG.sub.35-55 on day 0, the CD19.sup.-/- mice received saline (PBS)
or purified spleen CD1d.sup.hiCD5.sup.+ or CD1d.sup.loCD5.sup.- B
cells from either wild type, IL-10.sup.-/-, IL-21R.sup.-/-,
CD40.sup.-/-, or MHC-II.sup.-/- mice. The mice were scored daily
thereafter for disease severity.
[0014] The top two graphs show data from the same experiment, but
were separated since the curves superimposed and thus were
difficult to visualize on a single graph. (B) Graphs showing that
B10 cells require MHC-II expression to regulate EAE severity in
wild type mice treated with CD20 or control mAb 7 days before
MOG.sub.35-55 immunization on day 0. The mice also received PBS or
purified CD1d.sup.hiCD5.sup.+ B cells from either CD20.sup.-/- or
MHC-II.sup.-/- CD20.sup.-/- mice 1 day before MOG.sub.35-55
immunization. The two graphs are from the same experiment, but were
separated to facilitate visualization of the overlapping curves.
(C) Graph showing that activated MHC-II.sup.-/- B10 cells are not
able to reduce disease severity in wild type mice. Purified
CD1d.sup.hiCD5.sup.+ B cells from wild type or MHC-II.sup.-/- mice
were cultured with agonistic CD40 mAb for 48 h to induce B10pro
cell maturation, with LPS added during the final 5 h of culture.
Wild type mice were given either PBS or CD1d.sup.hiCD5.sup.+ B
cells 1 day before MOG.sub.35-55 immunization on day 0. In (A)-(C)
values represent mean (.+-.SEM) symptom scores from >3 mice in
each group, with similar results obtained in three independent
experiments. Significant differences between sample means are
indicated; *, p<0.05.
[0015] FIG. 3 is a set of data showing B10 cell expansion and
regulation of T cell-mediated autoimmunity. (A) Dot plots and
graphs showing that B10 cells require IL-10, IL-21R, CD40 and
MHC-II expression to regulate antigen-specific T cell proliferation
in vivo. CD19.sup.-/- recipient mice were given PBS as a control,
or purified CD1d.sup.hiCD5.sup.+ or CD1d.sup.loCD5.sup.- B cells
from naive wild type (WT), IL-10.sup.-/-, IL-21R.sup.-/-,
CD40.sup.-/- or MHC-II.sup.-/- mice, or wild type mice with EAE
(day 28) 1 day before MOG.sub.35-55 immunization on day 0. Four
days after immunization, dye (CFSE)-labeled TCR.sup.MOG CD4.sup.+
Thy1.1.sup.+ T cells were transferred into CD19.sup.-/- recipient
mice. Five days later, peripheral lymph node CD4.sup.+ Thy1.1.sup.+
T cells were analyzed for proliferation, with representative flow
cytometry analysis of CFSE dilution shown. Bar graphs indicate mean
(.+-.SEM) numbers of divided TCR.sup.MOG T cells. (B) Dot plots and
graphs showing that B10 cells require IL-10, IL-21R, CD40 and
MHC-II expression for their regulation of antigen-specific T cell
cytokine production. Purified CD1d.sup.hiCD5.sup.+ B cells from the
indicated mice were transferred into CD19.sup.-/- recipient mice 1
day before MOG.sub.35-55 immunization on day 0, with TCR.sup.MOG
Thy1.1.sup.+ CD4.sup.+ T cells transferred on day 4. Fourteen days
later, lymph node Thy1.1.sup.+ CD4.sup.+ T cells were analyzed for
IL-17 and IFN-.gamma. production by intracellular cytokine
staining, with representative flow cytometry results shown. Bar
graphs indicate mean (.+-.SEM) frequencies of cytokine-expressing
cells, with three mice in each group. In (A) and (B), significant
differences between sample means are indicated: *, p<0.05; **,
p<0.01. (C) A model for autoantigen (Ag)-specific B10 cell
function. B cells capture autoantigens that trigger appropriate BCR
signals (step 1) and promote IL-10-competent B10pro cell
development. During immune responses (step 2), B10pro cells present
peptides to antigen-specific T cells through cognate interactions
that induce T cell activation and CD40/CD154 interactions.
Activated T cells may produce IL-21 locally, which binds to
proximal B10 cell IL-21R (step 3). IL-21R signals induce B10 cell
IL-10 production and effector function (B10eff, step 4), which may
negatively regulate antigen-specific T cell function (step 5).
[0016] FIG. 4 is a set of data showing that IL-21 drives ex vivo
regulatory B10 cell expansion. (A) Dot plots showing B10 cell
development in vitro. Purified spleen B cells were cultured on a
monolayer of NIH-3T3 cells expressing CD154/BLyS in the presence of
exogenous IL-4 for 4 days, then cultured on fresh
NIH-3T3-CD154/BLyS cells with exogenous IL-21 for 3 or 5 days as
indicated. The cells were then isolated, cultured with monensin for
5 h and stained for cytoplasmic IL-10 expression. Representative
IL-10.sup.+ B cell frequencies within the indicated gates are
shown. Similar results were obtained in .gtoreq.10 experiments. (B)
A superimposed bar and line graph showing that IL-21 drives B10
cell expansion in vitro. B cells were cultured as in (A) with cells
harvested each day of culture. Bar values represent mean (.+-.SEM)
B cell and B10 cell numbers, or B10 cell frequencies (solid line)
from three independent experiments. (C) Dot plots showing
IL-21-induced B10 cells to express CD5. Wild type B cells were
cultured for 9 days as in (A) and stained for CD5 and CD19
expression. CD5.sup.+ and CD5.sup.- B cells were then purified by
cell sorting and cultured with monensin for 5 h before cytoplasmic
IL-10 staining. Results shown are representative of three
independent experiments (D) Graphs showing that IL-21-induced B10
effector cells inhibit EAE initiation and progression.
IL-21-induced B10 cells (CD5.sup.+ CD19.sup.+) or non-B10 cells
(CD5.sup.- CD19.sup.+) were isolated as in (C) and adoptively
transferred into wild type mice on days -1, 7, 14 or 21 (arrows)
before/after MOG immunization and EAE induction as in FIG. 2. (E)
Bar graph showing that B10 cell expansion in vitro requires IL-21R
and CD40 expression, and in vivo BCR signaling. Purified spleen B
cells isolated from wild type, IL-21R.sup.-/-, CD40.sup.-/-,
MHC-II.sup.-/-, CD19.sup.-/-, or MD4 mice were cultured as in (A),
with mean (.+-.SEM) cell numbers quantified after culture. Values
represent means (.+-.SEM) of three independent experiments.
IL-10.sup.+ B cell frequencies in the cultures are shown in
parentheses. (F) Graphs showing that IL-21-induced B10 cells
require IL-10 and MHC-II expression to inhibit EAE. B cells from
IL-10.sup.-/- or MHC-II.sup.-/- mice were cultured as in (A),
separated into CD5.sup.+ or CD5.sup.- cells as in (C) and
adoptively transferred into wild type mice before MOG.sub.35-55
immunization as in (D). In (D) and (F), values represent mean
(.+-.SEM) symptom scores from .gtoreq.3 mice in each group, with
similar results obtained in three independent experiments. In (B),
(D) and (E), significant differences between sample means are
indicated: *, p<0.05; **, p<0.01.
[0017] FIG. 5 presents a set of data showing that IL-21 induces
regulatory B10 cell function. (A) Bar graphs showing that IL-21
induces B10 cell IL-10 production and secretion. Spleen CD19.sup.+
B cells purified from wild type mice were cultured with medium
alone or with the indicated cytokines for 48 or 72 h. To visualize
IL-10-competent B cells, monensin was added to the cultures 5 h
before the cells were isolated, stained with CD19 mAb,
permeabilized, stained for cytoplasmic IL-10 expression and
analyzed by flow cytometry. Bar graphs indicate mean (.+-.SEM)
IL-10.sup.+ B cell frequencies or numbers at 48 and 72 h from
individual mice in three independent experiments. Significant
differences between media versus cytokine sample means are
indicated: *, p<0.05; **, p<0.01. (B-D) Dot plots and bar
graphs showing IL-21R, CD40 and MHC-II expression are not required
for B10 or B10pro cell development, respectively. Purified spleen B
cells from wild type and IL-21R.sup.-/- (B) CD40.sup.-/- (C) or
MHC-II.sup.-/- (D) mice were cultured with monensin alone or L+PIM
for 5 h to quantify B10 cell frequencies. Alternatively, B10+B10pro
cell frequencies were determined after culturing the cells ex vivo
with agonistic CD40 mAb for 48 h, with L+PIM added during the final
5 h of culture. Representative histograms and bar graphs indicate
mean (.+-.SEM; .gtoreq.3 mice per group) percentages and numbers of
B cells that expressed IL-10 in one of two experiments with
equivalent results.
[0018] FIG. 6 is a set of dot blots and bar graphs showing that T
follicular helper cells are present in CD19.sup.-/- mice.
Representative flow cytometry analysis of CXCR5.sup.hiPD1.sup.+
cells among spleen CD4.sup.+ T cells from wild type and
CD19.sup.-/- mice. Bar values represent mean (.+-.SEM)
CXCR5.sup.hiPD1.sup.+ cell frequencies among CD4.sup.+ T cells from
three mice. Significant differences between sample means are
indicated: *, p<0.05.
[0019] FIG. 7 is a graph showing the total number of B cells and
B10 cells after the indicated time in culture and the amount of
IL-10 produced by the culture. Purified human blood B cells were
cultured on NIH-3T3-mCD154/hBLyS cell monolayers with exogenous
human IL-4 (2 ng/ml) for 7 days. Additional media containing IL-4
(2 ng/ml) was added to the cultures on days 2 and 4. The B cells
were then isolated and cultured on fresh NIH-3T3-CD154/BLyS cells
with exogenous human IL-21 (10 ng/ml) for 5 days as indicated. The
cells were then isolated, cultured with CpG+PIB for 5 h and stained
for cell surface CD19 and cytoplasmic IL-10 expression. Bar values
represent mean (.+-.SEM) CD19.sup.+ B cell and B10 cell numbers, or
B10 cell frequencies (solid line) from two independent
experiments.
DETAILED DESCRIPTION
[0020] The B10 cell subset of regulatory B cells has been
functionally defined in humans and mice by their ability to express
IL-10. B cells that are competent to express IL-10 following 5 h of
ex vivo phorbol ester and ionomycin stimulation are functionally
defined as B10 cells to distinguish them from other regulatory B
cells that modulate immune responses through other mechanisms. B10
cells are found at low frequencies (1-5%) in naive mice but expand
with autoimmunity. Spleen B10 cells are predominantly found within
the minor CD1d.sup.hiCD5.sup.+ B cell subpopulation along with rare
B10 progenitor (B10pro) cells that are induced to become
IL-10-competent during in vitro culture with agonistic CD40
monoclonal antibody (mAb). The capacity of human and mouse B10
cells to produce IL-10 is central to their ability to negatively
regulate inflammation and autoimmune disease, as well as adaptive
and innate immune responses, but the physiologic signals that
control IL-10 production in vivo are unknown.
[0021] B10 cell immunoregulation is antigen-specific, and B cell
antigen receptor (BCR) specificity dramatically influences B10 cell
development. Receptors or pathways that positively or negatively
regulate BCR signaling can also modulate B10 cell numbers in vivo.
For example, CD19-deficient (CD19.sup.-/-) mice are essentially
devoid of regulatory B10 cells, which leads to exacerbated
inflammation and disease symptoms during contact hypersensitivity
and in the experimental autoimmune encephalomyelitis (EAE) model of
multiple sclerosis. IL-10 itself is not required for B10 cell
development since B cells with the capacity to express IL-10
reporter genes develop normally in IL-10.sup.-/- mice. B10 cell
numbers are also normal in T cell-deficient nude mice and in mice
deficient in expression of major histocompatibility complex class
II (MHC-II) or CD40 molecules that are important for cognate B
cell-T cell interactions. Consequently, appropriate BCR signals are
thought to select a subset of B cells to become IL-10-competent B10
cells. Innate pathogen-induced signals also influence regulatory
B10 cell development in vivo. Little is otherwise known about how
B10 cell IL-10 production is regulated in vivo, and it remains
unclear how such rare B cells exert such potent in vivo effects and
selectively inhibit antigen-specific T cell function during
inflammation and autoimmunity.
[0022] Using a mouse model for multiple sclerosis, we show here
that B10 cell maturation into functional IL-10-secreting effector
cells that inhibit in vivo autoimmune disease requires IL-21 and
CD40-dependent cognate interactions with T cells. Moreover, the ex
vivo provision of CD40 and IL-21 receptor signals can drive B10
cell development and expansion by up to four-million-fold and
generate B10 effector cells producing IL-10 that dramatically
inhibit disease symptoms when transferred into mice with
established autoimmune disease. Thereby, the ex vivo expansion and
reinfusion of autologous B10 cells may provide a novel and
effective in vivo treatment for autoimmune diseases and other
conditions that are resistant to current therapies.
[0023] In addition, we also show that human B cells and B10 cells
can be expanded ex vivo. The B cells were harvested from normal
human blood and expanded ex vivo using the same methods as were
used for expansion of mouse B cells. As described in the Examples,
B cell numbers were increased by 130 fold while B10 cells were
increased by 5-6,000 fold. Thus, the examples demonstrate that the
methods may be used to generate ex vivo expanded B cells that may
be useful for autologous treatment of human diseases or conditions
in which addition of responsive B cells or of B10 cells may be
therapeutic.
Methods of Expanding B Cells Ex Vivo
[0024] Described herein are methods of expanding polyclonal B cells
and specifically B10 cells ex vivo. The methods include harvesting
B cells from a subject and incubating them with IL-21. In FIG. 1,
the B10 cells were expanded over two fold after 48 hours of ex vivo
incubation with IL-21 at 100 ng/ml and over three fold after 72
hours incubation. The methods may further include incubation with a
CD40 ligand, and a B cell survival promoter such as BAFF (BLyS,
used interchangeably herein) or feeder cells expressing a CD40
ligand and/or BAFF to result in further expansion of B cells and
B10 cells. As shown in the Examples, the B cells may be further
expanded ex vivo by a first incubation with IL-4 followed by a
second incubation including IL-21. Either or both of these steps
may include feeder cells and optionally a CD40 ligand and/or BAFF.
Total B cells were expanded using the methods described herein, but
B10 cells were expanded at a higher frequency using these methods.
In addition, the B10 cells were able to produce IL-10 without a
need for further stimulation ex vivo with LPS or another
stimulatory signal. Suitably, the B cells are human B cells.
[0025] In an alternative embodiment of the methods of expanding B
cells described herein, the B cells are harvested from a subject
and then incubated on feeder cells expressing a CD40 agonist and a
B cell survival promoter such as BAFF in the presence of IL-4. This
incubation period may last from two to ten or more days and the
amount of IL-4 may be optimized. In the methods, 2 ng/ml IL-4 was
used, but 0.5 ng/ml to 100 ng/ml may be useful. The resultant cells
were then incubated on the feeder cells expressing CD40 agonist and
a B cell survival promoter such as BAFF in the presence of IL-21
for an additional two to eight or more days before harvesting the
expanded B cells. In the Examples, either 10 ng/ml or 100 ng/ml of
IL-21 was used, but between 5 ng/ml and 1000 ng/ml of IL-21 may be
used. The actual amount of IL-4 and IL-21 used in the methods can
be determined by those of skill in the art and will depend on the
culture conditions, including whether the culture media and the
cytokines were replenished over time, the length of the culture
period and other culture conditions. In the Examples, total
polyclonal B cells and B10 cells were expanded using this method.
However, the cultures may start with single B cells or isolated B
cell subsets that are then expanded ex vivo into monoclonal,
pauciclonal or polyclonal B cell populations. The B cells produce
antibodies under the culture conditions described herein and thus
the methods may be used to select for a monoclonal, pauciclonal or
polyclonal population of antibody producing B cells. Suitably, the
B cells are mouse B cells, Suitably the B cells are human B
cells.
[0026] The B cells used in the methods may be harvested from
various areas of the subject, including but not limited to the
blood, spleen, peritoneal cavity, lymph nodes, bone marrow, site of
autoimmune disease, site of inflammation or tissue undergoing
transplant rejection in the subject. The cells may be harvested
from the subject by any means available to those of skill in the
art. The harvested population of cells should contain B cells, but
may be a mixed cellular population. The subject may be any animal
with B lymphocytes, suitably a mammal, suitably a domesticated
animal such as a horse, cow, pig, cat, dog, or chicken, or suitably
a human. Alternatively, the cells may be derived from stem cells,
including but not limited to B cell stem cells, bone marrow stem
cells, embryonic stem cells and induced pluripotent stem cells,
which have been appropriately differentiated in vitro to develop
into B cells or B cell progenitors prior to use in the methods
described herein. See e.g., Carpenter et al., 2011, Blood 117:
4008-4011.
[0027] The B cells may be isolated from the subject by removal of
non-B cells, or selection for cell surface markers such as IgM,
IgD, IgG, IgA, IgE, CD19, CD20, CD21, CD22, CD24, CD40, CD72, CD79a
or CD79b, or combinations of these cell surface molecules including
CD1d, CD5, CD9, CD10, CD23, CD27, CD38, CD48, CD80, CD86, CD138 or
CD148. The expanded B cells may be harvested by selecting for these
markers after ex vivo culturing in the method or specific B cell
types, such as B10 cells, may be selected using these markers
before or after ex vivo expansion either alone or in combination.
The B10 cells may be harvested by selecting for CD1d, CD5, CD24,
CD27 or combinations thereof. In some embodiments, the B10 cells
are capable of producing IL-10 after incubation with IL-21 and thus
may be selected, isolated or harvested by selecting for IL-10
production. In other embodiments, the B10 cells may need to be
further stimulated to produce IL-10 with e.g., LPS or PMA and
ionomycin. Methods of stimulating B10 cells to produce IL-10 are
known in the art and include stimulation with LPS or CpG
oligonucleotides.
[0028] As used herein expansion of B cells includes stimulation of
proliferation of the cells as well as prevention of apoptosis or
other death of the cells. As used herein, "culturing" and
"incubation" are used to indicate that the cells are maintained in
cell culture medium at 37.degree. C. and 5% CO.sub.2 for a period
of time with the indicated additives (feeder cells, cytokines,
agonists, other stimulatory molecules or media, which may include
buffers, salts, sugars, serum or various other constituents).
Suitably, the incubation or culturing periods used herein is at
least 48 hours, but may be for any amount of time up to eight or
more days. As shown in the Examples more than one culturing period
may be used. In the Examples, for mouse B cell expansion the
culture with IL-4 was four days long and the culture with IL-21 was
five days. For human B cells, the expansion with IL-4 was a seven
day culture period followed by a five day culture with IL-21. Those
of skill in the art will appreciate that the culturing or
incubation time may be varied to allow proper expansion, to adjust
for different cell densities or frequencies of individual subsets,
and to allow an investigator to properly time use of the cells.
Thus the precise culture length may be determined empirically by
one of skill in the art.
[0029] As used herein, isolating is used to indicate that a group
of cells is separated from incubation media, feeder cells or other
non-B cells. Isolating is not meant to convey that the resulting
isolated cells have a certain level of purity or homogeneity. The
cells may be harvested, isolated or selected using any means
available to those of skill in the art. For example, B cells may be
harvested from adherent cells by selecting for non-adherent cells
after an appropriate incubation. Cells may also be selected for
expression of cell surface markers by FACS sorting or by the
differential ability to bind antibody coated magnetic beads. Means
of selecting cells in a mixed population are well known to those
skilled in the art.
[0030] Non-limiting examples of CD40 agonists include CD40
antibodies and fragments thereof, the CD40 ligand (CD154) and
polypeptide fragments thereof, small molecules, synthetic drugs,
peptides (including cyclic peptides), polypeptides, proteins,
nucleic acids, aptamers, synthetic or natural inorganic molecules,
mimetic agents, and synthetic or natural organic molecules. In a
certain embodiment, the CD40 agonist is a CD40 antibody. The CD40
antibodies can be of any form. Antibodies to CD40 are known in the
art (see, e.g., Buhtoiarov et al., 2005, J. Immunol. 174:6013-22;
Francisco et al., 2000, Cancer Res. 60:3225-31; Schwulst et al.,
2006, 177:557-65, herein incorporated by reference in their
entireties). The CD40 agonists may be CD40 ligands and may be
expressed on the surface of feeder cells or soluble.
[0031] The BAFF (BLyS) may be expressed by the feeder cells via
methods known to those of skill in the art. The BLyS may be
expressed on the surface or may be soluble after cleaved from the
cell surface. Alternatively the BAFF is replaced by a different
factor(s) that promotes B cell survival in culture including feeder
cells, BAFF fragments, APRIL, CD22 ligand, CD22 monoclonal
antibody, or fragments thereof.
[0032] The feeder cells used in the Examples were fibroblasts but
other feeder cells may be used in the methods. The feeder cells may
be endothelial cells, epithelial cells, keratinocytes, melanocytes,
or other mesenchymal or stromal cells. The incubation or culturing
periods used in the methods may be from two to ten or more days for
each step in the method. Suitably, the incubation time is between
three and seven days, suitably it is between four and five days. As
described in the examples the feeder cells are likely required to
supply additional signals, other than the CD40 agonist and BAFF, to
allow optimal B cell expansion in the methods. A preliminary
analysis of other factors supplied by the feeder cells to optimize
B cell expansion is included in the Examples and Table 1 below. In
summary, in addition to a CD40 agonist and BAFF, the feeder cells
minimally express VCAM-1 and CD44 in addition to CD40 agonist and
BAFF. Increased expression of CD24, interleukin-7 (IL-7), Mst1 and
Tslp by the feeder cells correlated with the feeder cells being
capable of producing increased numbers of B cells during ex vivo
expansion. Similarly, downregulation of certain molecules in the
feeder cells correlated with increased ability to support B cell
expansion. In particular, downregulation of CD99, TGFBI, CXCR7,
Dlk1, Jag1 and Notch1 on the feeder cells correlated with the cells
being better capable of supporting B cell expansion ex vivo. Thus,
those of skill in the art may be able to select for, or create via
genetic engineering, feeder cells better capable of supporting B
cell expansion ex vivo. The information may also be used to
generate a means of expanding B cells that does not require live
feeder cells for optimal ex vivo B cell expansion.
[0033] The methods may allow from two fold to over 5.times.10.sup.6
fold expansion of B cells or B10 cells in particular. The cells may
be selected after the culture period to remove any non-B cells or
to positively select for B cells or for a particular B cell subset
such as B10 cells. The B10 cells may represent 10%, 15%, 20%, 25%,
30%, 35%, 40% or more of the total B cells in the culture after the
expansion method is complete. After selecting the cells for cell
surface expression of a B10 cell surface marker(s) more than 50%,
55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% of the cells are B10 or
B10pro cells capable of producing IL-10.
[0034] Compositions Comprising the Expanded B Cells
[0035] Compositions including the expanded polyclonal B cells
generated using the methods described herein are also provided. In
one aspect, the compositions include more than 50%, 55%, 60%, 65%,
70%, 75%, 80%, 85%, 90%, 95%, 98%, 99% or substantially 100% B10 or
B10pro cells. In other aspects the compositions are selected to
include antibody producing B cells. The compositions may include
more than 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%,
99% or substantially 100% antibody producing B cells.
[0036] The expanded B cell containing compositions may be used to
make pharmaceutical compositions. Pharmaceutical compositions
comprising the expanded B cells described above and a
pharmaceutically acceptable carrier are provided. A
pharmaceutically acceptable carrier is any carrier suitable for in
vivo administration of cells. Examples of pharmaceutically
acceptable carriers suitable for use in the composition include,
but are not limited to, buffered solutions, glucose solutions,
oil-based or cellular culture based fluids. Additional components
of the compositions may suitably include, for example, excipients
such as stabilizers, preservatives, diluents, emulsifiers and
lubricants. Examples of pharmaceutically acceptable carriers or
diluents include stabilizers such as carbohydrates (e.g., sorbitol,
mannitol, starch, sucrose, glucose, dextran), proteins such as
albumin or casein, protein-containing agents such as bovine serum
or skimmed milk and buffers (e.g., phosphate buffer).
[0037] The expanded B cell compositions may be co-administered with
other treatments, such as small molecule, polypeptide, antibody,
aptamer or other therapeutics. Co-administration of the
compositions described herein with another therapeutic may be
administered in any order, at the same time or as part of a unitary
composition. The two compositions may be administered such that one
composition is administered before the other with a difference in
administration time of 1 hour, 2 hours, 4 hours, 8 hours, 12 hours,
16 hours, 20 hours, 1 day, 2 days, 4 days, 7 days, 2 weeks, 4 weeks
or more.
[0038] In another embodiment, the B cell or B10 cell population may
be monoclonal or pauciclonally expanded from isolated single cells
or isolated B cell subsets. In one aspect, the compositions include
more than 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%,
65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99% or substantially 100%
monoclonal B cells or B10 cells. In other aspects the compositions
are selected to include antibody producing B cells. The
compositions may include more than 10%, 15%, 20%, 25%, 30%, 35%,
40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%,
99% or substantially 100% antibody producing B cells. In another
aspect the compositions are selected to include monoclonal or
pauciclonal antigen-specific B cells. The compositions may include
more than 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%,
65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99% or substantially 100% B
cells specific for or producing antibody against a single protein
or other antigenic entity. In another aspect, the compositions may
include more than 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%,
98%, 99% or substantially 100% B cells capable of exerting
regulatory activities by expressing IL-113, IL-2, IL-4, IL-5, IL-6,
IL-12, IL-13, IL-17, IFN.gamma., IL-23 or TNF-.alpha..
[0039] In another embodiment, the B cell or B10 cell population can
be made responsive to a certain antigen involved in a specific
disease. The B cells may produce therapeutic antibodies or other
cytokines in response to subsequent encounter with the antigen. The
B10 cell population, when sensitized with a certain antigen, may
produce therapeutic amounts of IL-10 upon subsequent encounters
with the antigen. Such antigen-specific B cell or B10 cell
populations may be used in adoptive transfer methods, wherein a
subject is or has previously been immunized with a certain antigen
and the antigen-sensitized cells from said subject are isolated,
expanded ex vivo by the methods described herein and transplanted
to the same or another subject. Alternatively, a B cell or B10 cell
population from a subject can be isolated and subsequently can be
sensitized with a disease-specific antigen ex vivo or in vitro. The
sensitized cell population can then be transplanted into the
original or another subject by any method known in the art. In
still another embodiment, the antigen-specific B cell or B10 cell
population can be added to an implantable immune modulation device.
According to this embodiment, the implanted cell population will
produce strategically localized IL-10, antibody or another cytokine
production when encountering antigen in the host, depending on the
cells implanted. In a further aspect, the B cell or B10 cell
population and a disease-specific antigen can both be placed in an
implantable immune modulation device, and said device then can be
transplanted into a recipient at a location where the therapeutic
effects of the cell population, i.e., IL-10 production, antibody
production or cytokine production, are needed, thus resulting in an
amplified response to the disease in vivo.
[0040] In another aspect, a certain disease-specific antigen can be
administered in conjunction with a CD40 agonist or a TLR agonist.
The therapeutic agent may be an antibody, in particular, a CD40
antibody or LPS or CpG oligodeoxynucleotides. In other aspects, the
therapeutic agent is a small molecule, a polypeptide, DNA, or RNA
that interacts with the B cell CD40 receptor or TLRs.
[0041] Any antigen from any disease, disorder, or condition may be
used in accordance with the methods of the invention. Exemplary
antigens include but are not limited to bacterial, viral,
parasitic, allergens, autoantigens and tumor-associated antigens.
If a DNA based vaccine is used the antigen will typically be
encoded by a sequence of the administered DNA construct.
Alternatively, if the antigen is administered as a conjugate the
antigen will typically be a protein comprised in the administered
conjugate. Particularly, the antigen can include protein antigens,
peptides, whole inactivated organisms, and the like.
[0042] Specific examples of antigens that can be used include, but
are not limited to, antigens from hepatitis A, B, C or D, influenza
virus, Listeria, Clostridium botulinum, tuberculosis, tularemia,
Variola major (smallpox), viral hemorrhagic fevers, Yersinia pestis
(plague), HIV, herpes, pappilloma virus, and other antigens
associated with infectious agents. Other antigens include antigens
associated with autoimmune conditions, inflammatory conditions,
allergy, asthma and transplant rejection. Non-limiting examples of
autoimmune diseases and inflammatory diseases are provided, infra.
As noted above, a B10 cell population sensitized with a
disease-specific antigen can be administered alone or in
conjunction with other therapeutic agents, such as a CD40 agonist
or TLR, in particular, a CD40 antibody, for use as a therapeutic or
prophylactic vaccine for treating a disease condition or for
suppressing immunity. Similarly, an expanded B cell composition
sensitized with a disease or microbe specific antigen may confer
immunity against such disease conditions or microbes.
[0043] In another embodiment, a B10 cell subset may be sensitized
with antigen from a prospective transplant donor, so as to increase
the levels of IL-10 production by the B10 cells in a transplant
recipient. The increased IL-10 production by the B10 cell subset in
the transplant recipient results in a decreased immune/inflammatory
response to the transplant in the transplant recipient. The role of
B10 cells in transplants is described more fully below.
Methods of Using the Expanded B Cell Compositions
[0044] The expanded B cell compositions may be used in methods of
treating subjects having a disease or condition. Such adoptive
transfer of B cells, and in particular B10 cells, can be effective
to suppress a wide variety of diseases, including, but not limited
to autoimmune diseases, inflammatory diseases, or any other disease
which may be treated by introduction of a B cell or B10 cell
population into a subject. Adoptive transfer of B cells or B10
cells can further be employed to minimize the immune/inflammatory
response associated with transplant of cells and/or tissues.
[0045] In an exemplary adoptive transfer protocol, a mixed
population of cells is initially extracted from a target donor.
Suitably, the B cells are selected, more suitably the B10 and
B10pro cells are selected from the subject. The cells isolated from
the donor may be isolated from any location in the donor in which
they reside including, but not limited to, the blood, spleen, lymph
nodes, and/or bone marrow of the donor as described more fully
above. Depending on the application, the cells may be extracted
from a healthy donor; a donor suffering from a disease that is in a
period of remission or during active disease; or from the organs,
blood, or tissues of a donor that has died. In the case of the
latter, the donor is an organ donor. In yet another embodiment, the
cells can be obtained from the subject, expanded and/or activated
and returned to the subject.
[0046] Harvested lymphocytes may be separated by flow cytometry or
other cell separation techniques based on B cell markers or B10
cell specific cell markers such as those described previously
(e.g., CD1d, CD5, CD24, and CD27), and then transfused to a
recipient. See also International Application Nos.
PCT/US2009/002560, PCT/US2011/46643 and PCT/US2011/066487, each of
which is incorporated herein by reference in its entirety.
Alternatively, the cells may be stored for future use. In one
aspect of this embodiment, the donor and the recipient are the same
subject. In another aspect of this embodiment, the donor is a
subject other than the recipient. In a further aspect of this
embodiment, the "donor" comprises multiple donors other than the
recipient, wherein the B10 cells from said multiple donors are
pooled. As discussed above, the B cells obtained from the donor are
expanded using the methods provided herein. The cells may also be
enriched, or made to produce elevated levels of IL-10 by methods
available to those of skill in the art prior to being administered
to a recipient.
[0047] In the methods of using the expanded B cells contemplated
herein, wherein the donor is a subject other than the recipient,
the recipient and the donor are histocompatible. Histocompatibility
is the property of having the same, or mostly the same, alleles of
a set of genes called the major histocompatibility complex (MHC).
These genes are expressed in most tissues as antigens. When
transplanted cells and/or tissues are rejected by a recipient, the
bulk of the immune system response is initiated through the MHC
proteins. MHC proteins are involved in the presentation of foreign
antigens to T cells, and receptors on the surface of the T cell are
uniquely suited to recognition of proteins of this type. MHC are
highly variable between individuals, and therefore the T cells from
the host may recognize the foreign MHC with a very high frequency
leading to powerful immune responses that cause rejection of
transplanted tissue. When the recipient and the donor are
histocompatible, the chance of rejection of the B10 cell population
by the recipient is minimized.
[0048] The amount of B cells or B10 cells which will be effective
in the treatment and/or suppression of a disease or disorder which
may be treated by introduction of a B cell or B10 cell population
into a subject can be determined by standard clinical techniques.
The dosage will depend on the type of disease to be treated, the
severity and course of the disease, the composition being
administered, the purpose of introducing the B cell or B10 cell
population, previous therapy the recipient has undertaken, the
recipient's clinical history and current condition, and the
discretion of the attending physician. For example, the specific
dose for a particular subject depends on age, body weight, general
state of health, diet, the timing and mode of administration, the
rate of excretion, medicaments used in combination and the severity
of the particular disorder to which the therapy is applied. Dosages
for a given patient can be determined using conventional
considerations, e.g., by customary comparison of the differential
activities of the compositions of the invention, such as by means
of an appropriate conventional pharmacological or prophylactic
protocol. The number of cells administered in the composition may
also be determined empirically.
[0049] The B10 cell population can be administered in treatment
regimes consistent with the disease, e.g., a single or a few doses
over one to several days to ameliorate a disease state or periodic
doses over an extended time to inhibit disease progression and
prevent disease recurrence. For example, the composition may be
administered two or more times separated by 4 hours, 6 hours, 8
hours, 12 hours, a day, two days, three days, four days, one week,
two weeks, or by three or more weeks. The precise dose to be
employed in the formulation will also depend on the route of
administration, the seriousness of the disease or disorder, and
whether the disease is chronic in nature and should be decided
according to the judgment of the practitioner and each patient's
circumstances.
[0050] The maximal dosage for a subject is the highest dosage that
does not cause undesirable or intolerable side effects. The number
of variables in regard to an individual prophylactic or treatment
regimen is large, and a considerable range of doses is expected.
The route of administration will also impact the dosage
requirements. It is anticipated that dosages of the compositions
will reduce symptoms of the condition at least 10%, 20%, 30%, 40%,
50%, 60%, 70%, 80%, 90% or 100% compared to pre-treatment symptoms
or symptoms is left untreated. It is specifically contemplated that
pharmaceutical preparations and compositions may palliate or
alleviate symptoms of the disease without providing a cure, or, in
some embodiments, may be used to cure the disease or disorder.
Effective doses may be extrapolated from dose-response curves
derived from in vitro or animal model test systems. Exemplary,
non-limiting doses that could be used in the treatment of human
subjects range from at least 4.times.10.sup.4, at least
4.times.10.sup.5, at least 4.times.10.sup.6, at least
4.times.10.sup.7, at least 4.times.10.sup.8, at least
4.times.10.sup.9, or at least 4.times.10.sup.10 B cells/m.sup.2. In
a certain embodiment, the dose used in the treatment of human
subjects ranges from about 4.times.10.sup.8 to about
4.times.10.sup.10 B cells/m.sup.2.
[0051] For use in the methods described herein, the compositions
may be administered by any means known to those skilled in the art,
including, but not limited to, intraperitoneal, parenteral,
intravenous, intramuscular, subcutaneous, or intrathecal. Thus the
compositions may suitably be formulated as an injectable
formulation. Administration of the compositions to a subject in
accordance with the invention appears to exhibit beneficial effects
in a dose-dependent manner. Thus, within broad limits,
administration of larger quantities of the compositions is expected
to achieve increased beneficial biological effects than
administration of a smaller amount. Moreover, efficacy is also
contemplated at dosages below the level at which toxicity is
seen.
[0052] In another aspect, the B cells or B10 cells obtained from
the donor can be introduced into a recipient at a desired location,
so as to specifically target the therapeutic effects of the B cell
or B10 cell population, i.e., IL-10 production or antibody
secretion. Such techniques can be accomplished using implantable
immune modulation devices, e.g., virtual lymph nodes, such as those
described in U.S. patent application publication No. 2003/0118630;
WO1999/044583; and U.S. Pat. No. 6,645,500, which are incorporated
by reference herein in their entireties. According to this
embodiment, a B cell or B10 cell population can be isolated from a
donor as described above, added to an implantable immune modulation
device, and said device then can be implanted into a recipient at a
location where the therapeutic effects of the B cell or B10 cell
population, i.e., antibodies or IL-10 production, are needed.
[0053] By the terms "treat," "treating" or "treatment of" (or
grammatically equivalent terms) it is meant that the severity of
the subject's condition is reduced or at least partially improved
or ameliorated and/or that some alleviation, mitigation or decrease
in at least one clinical symptom is achieved and/or there is an
inhibition or delay in the progression of the condition and/or
prevention or delay of the onset of a disease or illness. The terms
"treat," "treating" or "treatment of" also means managing an
autoimmune disease or disorder. Thus, the terms "treat," "treating"
or "treatment of" (or grammatically equivalent terms) refer to both
prophylactic and therapeutic treatment regimes.
[0054] As used herein, a "sufficient amount" or "an amount
sufficient to" achieve a particular result refers to a number of
B10 or B10 effector cells of the invention that is effective to
produce a desired effect, which is optionally a therapeutic effect
(i.e., by administration of a therapeutically effective amount).
For example, a "sufficient amount" or "an amount sufficient to" can
be an amount that is effective to alter the severity of the
subject's condition.
[0055] A "therapeutically effective" amount as used herein is an
amount that provides some improvement or benefit to the subject.
Alternatively stated, a "therapeutically effective" amount is an
amount that provides some alleviation, mitigation and/or decrease
in at least one clinical symptom. Clinical symptoms associated with
the disorders that can be treated by the methods of the invention
are well-known to those skilled in the art. Further, those skilled
in the art will appreciate that the therapeutic effects need not be
complete or curative, as long as some benefit is provided to the
subject. It is likely that the "therapeutically effective" number
of cells required to "treat" an individual will depend on the
source of the B cells, the immunological status of the patient at
time of blood harvest, the condition of the individual at the time
of treatment, and the level of therapeutic treatment with
immunosuppressive drugs or agents at the time of treatment as
well-known to those skilled in the art.
Specific Diseases or Conditions Treatable in the Methods
[0056] Autoimmune Diseases
[0057] Diseases and conditions associated with diminished IL-10
levels can be treated in accordance with this aspect of the
invention. Decreased levels of IL-10 have been demonstrated in
autoimmune and inflammatory diseases including, but not limited to
psoriasis (Asadullah et al., 1998, J. Clin. Investig. 101:783-94,
Nickoloff et al., 1994, Clin. Immunol. Immunopathol., 73:63-8,
Mussi et al. 1994, J. Biol. Regul. Homeostatic Agents), rheumatoid
arthritis (Jenkins et al., 1994, Lymphokine Cytokine Res. 13:47-54;
Cush et al., 1995, Arthritis Rheum. 38:96-104; Al Janadi et al.,
1996, J. Clin. Immunol. 16:198-207), allergic contact dermatitis
(Kondo et al., 1994, J. Investig. Dermatol. 103:811-14; Schwarz et
al., 1994, J. Investig. Dermatol. 103:211-16), inflammatory bowel
disease (Kuhn et al., 1993, Cell 75:263-74; Lindsay and Hodgson,
2001, Aliment. Pharmacol. Ther. 15:1709-16) and multiple sclerosis
(Barrat et al., 2002, J. Exp. Med. 195:603-16; Cua et al., 2001, J.
Immunol. 166:602-8; Massey et al., 2002, Vet. Immunol.
Immunopathol. 87:357-72; Link and Xiao, 2001, Immunol. Rev.
184:117-28).
[0058] Any type of autoimmune disease can be treated in accordance
with this method of the invention. The term "autoimmune disease or
disorder" refers to a condition in a subject characterized by
cellular, tissue and/or organ injury caused by an immunologic
reaction of the subject to its own cells, tissues and/or organs.
The term "inflammatory disease" is used interchangeably with the
term "inflammatory disorder" to refer to a condition in a subject
characterized by inflammation, preferably chronic inflammation.
Autoimmune disorders may or may not be associated with
inflammation. Moreover, inflammation may or may not be caused by an
autoimmune disorder. Thus, certain disorders may be characterized
as both autoimmune and inflammatory disorders.
[0059] Exemplary autoimmune diseases or disorders include, but are
not limited to: allergic contact dermatitis, allergic reactions to
drugs, alopecia areata, ankylosing spondylitis, antiphospholipid
syndrome, autoimmune Addison's disease, autoimmune diseases of the
adrenal gland, autoimmune hemolytic anemia, autoimmune hepatitis,
autoimmune oophoritis and orchitis, autoimmune thrombocytopenia,
Behcet's disease, bullous pemphigoid and associated skin diseases,
cardiomyopathy, Celiac disease, Celiac sprue-dermatitis, chronic
fatigue immune dysfunction syndrome (CFIDS), chronic inflammatory
demyelinating polyneuropathy, Churg-Strauss syndrome, cicatrical
pemphigoid, CREST syndrome, cold agglutinin disease, Crohn's
disease, cutaneous necrotizing venulitis, discoid lupus, erythema
multiforme, essential mixed cryoglobulinemia,
fibromyalgia-fibromyositis, glomerulonephritis, Graves' disease,
Guillain-Barre, Hashimoto's thyroiditis, idiopathic pulmonary
fibrosis, idiopathic/autoimmune thrombocytopenia purpura (ITP),
immunologic lung disease, immunologic renal disease, IgA
neuropathy, juvenile arthritis, lichen planus, lupus erthematosus,
Meniere's disease, mixed connective tissue disease, multiple
sclerosis, type 1 or immune-mediated diabetes mellitus, myasthenia
gravis, pemphigus-related disorders (e.g., pemphigus vulgaris),
pernicious anemia, polyarteritis nodosa, polychrondritis,
polyglandular syndromes, polymyalgia rheumatica, polymyositis and
dermatomyositis, primary agammaglobulinemia, primary biliary
cirrhosis, psoriasis, psoriatic arthritis, Raynauld's phenomenon,
Reiter's syndrome, Rheumatoid arthritis, rheumatic fever,
sarcoidosis, scleroderma, Sjogren's syndrome, stiff-man syndrome,
spondyloarthropathies, systemic lupus erythematosis (SLE), lupus
erythematosus, systemic vasculitis, takayasu arteritis, temporal
arteristis/giant cell arteritis, thrombocytopenia, thyroiditis,
ulcerative colitis, uveitis, vasculitides such as dermatitis
herpetiformis vasculitis, vitiligo, and Wegener's
granulomatosis.
[0060] The diagnosis of an autoimmune disease or disorder is
complicated in that each type of autoimmune disease or disorder
manifests differently among patients. This heterogeneity of
symptoms means that multiple factors are typically used to arrive
at a clinical diagnosis. Generally, clinicians use factors, such
as, but not limited to, the presence of autoantibodies, elevated
cytokine levels, specific organ dysfunction, skin rashes, joint
swelling, pain, bone remodeling, and/or loss of movement as primary
indicators of an autoimmune disease or disorder. For certain
autoimmune diseases or disorders, such as RA and SLE, standards for
diagnosis are known in the art. For certain autoimmune diseases or
disorders, stages of disease have been characterized and are well
known in the art. These art recognized methods for diagnosing
autoimmune diseases and disorders as well as stages of disease and
scales of activity and/or severity of disease that are well known
in the art can be used to identify patients and patient populations
in need of treatment for an autoimmune disease or disorder using
the compositions and methods described herein.
[0061] Diagnostic criteria for different autoimmune diseases or
disorders are known in the art. Historically, diagnosis is
typically based on a combination of physical symptoms. More
recently, molecular techniques such as gene-expression profiling
have been applied to develop molecular definitions of autoimmune
diseases or disorders. Exemplary methods for clinical diagnosis of
particular autoimmune diseases or disorders are provided below.
Other suitable methods will be apparent to those skilled in the
art. Also provided are methods of diagnosing and/or staging an
autoimmune disease based on B10 cell numbers or activity in a
subject.
[0062] In certain embodiments of the invention, patients with low
levels of autoimmune disease activity or patients with an early
stage of an autoimmune disease (for diseases where stages are
recognized) can be identified for treatment using the B10 cell
compositions and methods provided herein. The early diagnosis of
autoimmune diseases is difficult due to the general symptoms and
overlap of symptoms among diseases. In such embodiments, a patient
treated at an early stage or with low levels of an autoimmune
disease activity has symptoms comprising at least one symptom of an
autoimmune disease or disorder. In related embodiments, a patient
treated at an early stage or with low levels of an autoimmune
disease has symptoms comprising at least 1, 2, 3, 4, 5, 6, 7, 8, 9,
10, 11, 12, 13, 14, or 15 symptoms of an autoimmune disease or
disorder. The symptoms may be of any autoimmune diseases and
disorders or a combination thereof. Examples of autoimmune disease
and disorder symptoms are described below.
[0063] Rheumatoid Arthritis
[0064] Rheumatoid arthritis is a chronic disease, mainly
characterized by inflammation of the lining, or synovium, of the
joints. It can lead to long-term joint damage, resulting in chronic
pain, loss of function and disability. Identifying patients or
patient populations in need of treatment for rheumatoid arthritis
is a process. There is no definitive test that provides a positive
or negative diagnosis of rheumatoid arthritis. Clinicians rely on a
number of tools including, medical histories, physical exams, lab
tests, and X-rays.
[0065] Physical symptoms vary widely among patients and commonly
include, but are not limited to, joint swelling, joint tenderness,
loss of motion in joints, joint malalignment, fatigue, stiffness
(particularly in the morning and when sitting for long periods of
time), weakness, flu-like symptoms (including a low-grade fever),
pain associated with prolonged sitting, the occurrence of flares of
disease activity followed by remission or disease inactivity,
rheumatoid nodules or lumps of tissue under the skin (typically
found on the elbows, they can indicate more severe disease
activity), muscle pain, loss of appetite, depression, weight loss,
anemia, cold and/or sweaty hands and feet, and involvement of the
glands around the eyes and mouth, causing decreased production of
tears and saliva (Sjogren's syndrome). Apart from physical
symptoms, clinicians commonly use tests, such as, but not limited
to, complete blood count, erythrocyte sedimentation rate (ESR or
sed rate), C-reactive protein, rheumatoid factor, antinuclear
antibodies (ANA), imaging studies, radiographs (X-rays), magnetic
resonance imaging (MM) of joints or organs, joint ultrasound, and
bone densitometry (DEXA). These tests are examples of tests that
can be used in conjunction with the compositions and methods
described herein to check for abnormalities that might exist (i.e.,
identify patients or patient populations in need of treatment) or
to monitor side effects of drugs and check progress.
[0066] Early symptoms of rheumatoid arthritis commonly are found in
the smaller joints of the fingers, hands and wrists. Joint
involvement is usually symmetrical, meaning that if a joint hurts
on the left hand, the same joint will hurt on the right hand. In
general, more joint erosion indicates more severe disease
activity.
[0067] Symptoms of more advanced disease activity include damage to
cartilage, tendons, ligaments and bone, which causes deformity and
instability in the joints. The damage can lead to limited range of
motion, resulting in daily tasks (grasping a fork, combing hair,
buttoning a shirt) becoming more difficult. Skin ulcers, greater
susceptibility to infection, and a general decline in health are
also indicators of more advanced disease activity.
[0068] Progression of rheumatoid arthritis is commonly divided into
three stages. The first stage is the swelling of the synovial
lining, causing pain, warmth, stiffness, redness and swelling
around the joint. Second is the rapid division and growth of cells,
or pannus, which causes the synovium to thicken. In the third
stage, the inflamed cells release enzymes that may digest bone and
cartilage, often causing the involved joint to lose its shape and
alignment, more pain, and loss of movement.
[0069] Molecular techniques can also be used to to identify
patients or patient populations in need of treatment. For example,
rheumatoid arthritis has been shown to be associated with allelic
polymorphisms of the human leukocyte antigen (HLA)-DR4 and HLA-DRB1
genes. Rheumatoid arthritis patients frequently express two
disease-associated HLA-DRB1*04 alleles. Patients can be tested for
allelic polymorphisms using methods standard in the art. MHC genes
are not the only germline-encoded genes influencing susceptibility
to RA that can be used to diagnose or identify patients or patient
populations in need of treatment. Female sex clearly increases the
risk, and female patients develop a different phenotype of the
disease than do male patients. Any molecular indicators of
rheumatoid arthritis can be used to identify patients or patient
populations in need of treatment with B10 cell compositions and
methods described herein.
[0070] In certain embodiments of the methods, a patient can be
treated with B10 cell compositions prior, concurrent, or subsequent
to other therapies, such as, but not limited to surgery. For
example, patients in need of treatment for rheumatoid arthritis
commonly undergo surgical treatment, such as, but not limited to,
synovectomy to reduce the amount of inflammatory tissue by removing
the diseased synovium or lining of the joint; arthroscopic surgery
to take tissue samples, remove loose cartilage, repair tears,
smooth a rough surface or remove diseased synovial tissue;
osteotomy, meaning "to cut bone," this procedure is used to
increase stability by redistributing the weight on the joint; joint
replacement surgery or arthroplasty for the surgical reconstruction
or replacement of a joint; or arthrodesis or fusion to fuse two
bones together. Such surgical procedures are examples of treatment
that patients can undergo prior, concurrent, or subsequent to
treatment with the methods and compositions provided herein. In one
embodiment, the B10 cell compositions may be administered locally
at the site of surgery either before, during or after surgery to
protect the joint from further attack or degradation.
[0071] Systemic Lupus Erythematosis (SLE)
[0072] Systemic lupus erythematosis (SLE) is a chronic
(long-lasting) rheumatic disease which affects joints, muscles and
other parts of the body. Patients or patient populations in need of
treatment for SLE can be identified by examining physical symptoms
and/or laboraotry test results. Physical symptoms vary widely among
patients. For example, in SLE, typically 4 of the following 11
symptoms exist before a patient is diagnosed with SLE: 1) malar
rash: rash over the cheeks; 2) discoid rash: red raised patches; 3)
photosensitivity: reaction to sunlight, resulting in the
development of or increase in skin rash; 4) oral ulcers: ulcers in
the nose or mouth, usually painless; 5) arthritis: nonerosive
arthritis involving two or more peripheral joints (arthritis in
which the bones around the joints do not become destroyed); 6)
serositis pleuritis or pericarditis: (inflammation of the lining of
the lung or heart); 7) renal disorder: excessive protein in the
urine (greater than 0.5 gm/day or 3+ on test sticks) and/or
cellular casts (abnormal elements the urine, derived from red
and/or white cells and/or kidney tubule cells); 8) neurologic
disorder: seizures (convulsions) and/or psychosis in the absence of
drugs or metabolic disturbances which are known to cause such
effects; 9) hematologic disorder: hemolytic anemia or leukopenia
(white blood count below 4,000 cells per cubic millimeter) or
lymphopenia (less than 1,500 lymphocytes per cubic millimeter) or
thrombocytopenia (less than 100,000 platelets per cubic millimeter)
(The leukopenia and lymphopenia must be detected on two or more
occasions. The thrombocytopenia must be detected in the absence of
drugs known to induce it); 10) antinuclear antibody: positive test
for antinuclear antibodies (ana) in the absence of drugs known to
induce it; and/or 11) immunologic disorder: positive anti-double
stranded anti-DNA test, positive anti-sm test, positive
antiphospholipid antibody such as anticardiolipin, or false
positive syphilis test (vdrl).
[0073] Other physical symptoms that may be indicative of SLE
include, but are not limited to, anemia, fatigue, fever, skin rash,
muscle aches, nausea, vomiting and diarrhea, swollen glands, lack
of appetite, sensitivity to cold (Raynaud's phenomenon), and weight
loss.
[0074] Laboratory tests can also be used to to identify patients or
patient populations in need of treatment. For example, a blood test
can be used to detect a group of autoantibodies found in the blood
of almost all people with SLE; a compliment test (C3, C4, CH50,
CH100) can be used to measure the amount of complementary proteins
circulating in the blood, a sedimentation rate (ESR) or C-reactive
protein (CRP) may be used to measure inflammation levels, a urine
analysis can be used to detect kidney problems, chest X-rays may be
taken to detect lung damage, and an EKG can be used to detect heart
problems. These tests are examples of tests that can be used in
conjunction with the compositions and methods described herein to
check for abnormalities that might exist (i.e., identify patients
or patient populations in need of treatment) or to monitor side
effects of drugs and check progress.
[0075] Idiopathic/Autoimmune Thrombocytopenia Purpura (ITP)
[0076] Idiopathic/autoimmune thrombocytopenia purpura (ITP) is a
disorder of the blood characterized by immunoglobulin G (IgG)
autoantibodies that interact with platelet cells resulting in
destruction of those platelet cells. Typically, the antibodies are
specific to platelet membrane glycoproteins. The disorder may be
acute (temporary, lasting less than 2 months) or chronic
(persisting for longer than 6 months). Patients or patient
populations in need of treatment for ITP can be identified by
examining a patient's medical history, physical symptoms, and/or
laboratory test results.
[0077] Physical symptoms include purplish-looking areas of the skin
and mucous membranes (such as the lining of the mouth) where
bleeding has occurred as a result of a decrease in the number of
platelet cells. The main symptom is bleeding, which can include
bruising ("ecchymosis") and tiny red dots on the skin or mucous
membranes ("petechiae"). In some instances bleeding from the nose,
gums, digestive or urinary tracts may also occur. Rarely, bleeding
within the brain occurs. Common signs, symptoms, and precipitating
factors also include, but are not limited to, abrupt onset
(childhood ITP), gradual onset (adult ITP), nonpalpable petechiae,
purpura, menorrhagia, epistaxis, gingival bleeding, hemorrhagic
bullae on mucous membranes, signs of GI bleeding, menometrorrhagia,
evidence of intracranial hemorrhage, nonpalpable spleen, retinal
hemorrhages, recent live virus immunization (childhood ITP), recent
viral illness (childhood ITP), spontaneous bleeding when platelet
count is less than 20,000/mm.sup.3, and bruising tendency.
[0078] Laboratory tests that can be used to diagnose ITP include,
but are not limited to, a complete blood count test, or a bone
marrow examination to verify that there are adequate
platelet-forming cells (megakaryocyte) in the marrow and to rule
out other diseases such as metastatic cancer and leukemia. Isolated
thrombocytopenia is the key finding regarding laboratory
evaluation. Giant platelets on peripheral smear are indicative of
congenital thrombocytopenia. A CT scan of the head may be warranted
if concern exists regarding intracranial hemorrhage. These tests
are examples of tests that can be used in conjunction with the
compositions and methods described herein to check for
abnormalities that might exist (i.e., identify patients or patient
populations in need of treatment) or to monitor side effects of
drugs and check progress.
[0079] Pemphigus-Related Disorders
[0080] Pemphigus-related disorders are characterized by a
blistering condition of the skin caused by the attack of antibodies
of certain proteins on the surface of skin cells. This attack
interferes with the ability of the skin cells to bind to each
other. There are three main types of pemphigus: pemphigus vulgaris,
pemphigus foliaceus and paraneoplastic pemphigus. Patients or
patient populations in need of treatment for pemphigus-related
disorders can be identified by examining a patient's medical
history, physical symptoms, and/or laboratory test results.
[0081] Typically, diagnosis of these pemphigus-related disorders is
made by skin biopsy. The biopsy skin sample can be treated using a
direct immunoflourescence technique to detect desmoglein antibodies
in the skin. Another diagnostic test that may be used is called
indirect immunofluorescence or antibody titer test. This measures
desmoglein autoantibodies in the blood serum. It may be used to
obtain a more complete understanding of the course of the disease.
In addition, a serum assay for desmoglein antibodies, an ELISA, is
also available. It is the most accurate. The presence of these
desmoglein autoantibodies in biopsy samples is diagnostic of
pemphigus generally.
[0082] Pemphigus vulgaris can be diagnosed by the presence of
blisters in the mouth. Inflammation or erosions may also be present
in the lining of the eye and eyelids, and the membranes of the nose
or genital tract. Half of the patients also develop blisters or
erosions of the skin, often in the groin, underarm, face, scalp and
chest areas. Pemphigus foliaceus is a superficial, relatively mild
form of pemphigus. It usually manifests on the face and scalp, but
also involves the back and chest. Lesions do not occur in the
mouth. The blisters are more confined to the outermost surface and
often itch. Paraneoplastic pemphigus is very rare and generally
occurs in people who have cancer. The lesions are painful and
affect the mouth, lips and esophagus (swallowing tube) as well as
the skin. Due to involvement of the airways, signs of respiratory
disease may occur and can be life-threatening. These tests are
examples of tests that can be used in conjunction with the
compositions and methods described herein to check for
abnormalities that might exist (i.e., identify patients or patient
populations in need of treatment) or to monitor side effects of
drugs and check progress.
[0083] Autoimmune Diabetes
[0084] A patient in need of treatment for type 1 diabetes can be
treated with the B10 cell compositions and methods described herein
as well. Type 1 diabetes is an autoimmune disease, in which the
body's immune system damages the islet cells in the pancreas,
reducing the production of insulin, resulting in high blood sugar.
Patients or patient populations in need of treatment for autoimmune
diabetes can be identified by examining a patient's medical
history, physical symptoms, and/or laboratory test results.
Symptoms often come on suddenly and include, but are not limited
to, increased thirst, increased urination, constant hunger, weight
loss, blurred vision, and fatigue.
[0085] Laboratory tests that can be used in identifying patients or
patient populations in need of treatment for autoimmune diabetes
include, but are not limited to, the direct measurement of glucose
levels in the blood during an overnight fast, and measurement of
the body's ability to appropriately handle the excess sugar
presented after drinking a high glucose drink. For the first test,
an elevated blood sugar level after an overnight fast (not eating
anything after midnight) can be used as a diagnostic factor. A
value above 140 mg/dl on at least two occasions typically means a
patient has diabetes. Normal patients have fasting sugar levels
that generally run between 70-110 mg/dl. For the second test, an
oral glucose tolerance test is typically performed. The patient
being tested starts the test in a fasting state (having no food or
drink except water for at least 10 hours but not greater than 16
hours). An initial blood sugar is drawn and then the patient is
given a "glucola" bottle with a high amount of sugar in it (75
grams of glucose), (or 100 grams for pregnant women). The patient
then has their blood tested again 30 minutes, 1 hour, 2 hours and 3
hours after drinking the high glucose drink. These tests are
examples of tests that can be used in conjunction with the
compositions and methods described herein to check for
abnormalities that might exist (i.e., identify patients or patient
populations in need of treatment) or to monitor side effects of
drugs and check progress.
[0086] Scleroderma
[0087] Scleroderma is a chronic skin and connective tissue disease.
In general, it is characterized by the formation of scar tissue in
the skin and organs of the body. Identification of patients and
patient populations in need of treatment of scleroderma can be
based on clinical history and physical findings. Patients or
patient populations in need of treatment for scleroderma can be
identified by examining a patient's medical history, physical
symptoms, and/or laboraotry test results. Diagnosis may be delayed
in patients without significant skin thickening. Laboratory, X-ray,
pulmonary function tests, and skin or renal (kidney) biopsies can
be used to determine the extent and severity of internal organ
involvement.
[0088] There are two types of scleroderma. Localized scleroderma
affects the skin in limited areas and the musculoskeletal system.
Systemic sclerosis causes more widespread skin changes and may be
associated with internal organ damage in the lungs, heart and
kidneys. Scleroderma shares symptoms that are common with other
autoimmune diseases, including but not limited to, numbness, pain
or color changes in fingers, toes, cheeks, nose and ears, often
brought on by cold or emotional distress (Raynaud's phenomenon),
stiffness or pain in your joints and curling of your fingers,
digestive problems ranging from poor absorption of nutrients to
delayed movement of food due to impaired muscular activity in your
intestine, sores over joints, such as your elbows and knuckles, and
puffy hands and feet, particularly in the morning. It can also
involve arthritis, muscle inflammation, dry eyes and dry mouth.
Most patients with scleroderma have cold-induced spasms of small
blood vessels in their hands or feet, known as Raynaud's
phenomenon, which causes the fingers or toes to turn white or blue
and may be painful. The symptoms of scleroderma vary greatly from
individual to individual, and the effects of scleroderma can range
from very mild to life-threatening.
[0089] Localized scleroderma has three main subtypes, which are
called morphea, generalized morphea and linear scleroderma.
Systemic type is the more serious type because it affects internal
organ systems. Its three subtypes are called limited, diffuse and
sine.
[0090] In the early months or years of disease onset, scleroderma
may resemble many other connective tissue diseases, such as, but
not limited to, Systemic Lupus Erythematosus, Polymyositis, and
Rheumatoid Arthritis.
[0091] The most classic symptom of systemic sclerosis (scleroderma)
is sclerodactyly. Initial symptoms include swollen hands, which
sometimes progress to this tapering and claw-like deformity. Not
everyone with scleroderma develops this degree of skin hardening.
Other symptoms can include morphea, linear sclerodactyly (hardened
fingers), Raynaud's syndrome, calcinosis, and telangiectasia.
[0092] Blood tests such as antinuclear antibody (ANA) tests can be
used in the diagnosis of both localized and systemic scleroderma.
For example, anti-centromere antibodies (ACA) and anti-Scl-70
antibodies are indicative of patients in need of treatment for
systemic sclerosis (Ho et al., 2003, Arthritis Res Ther. 5:80-93);
anti-topo II alpha antibody is indicative of patients in need of
treatment for local scleroderma; and anti-topo I alpha antibody is
indicative of patients in need of treatment for systemic
scleroderma.
[0093] Several types of scleroderma and methods for diagnosing
these types are recognized and well known in the art, including,
but not limited to, juvenile scleroderma; localized scleroderma;
Nodular Scleroderma; and Systemic scleroderma, including, but not
limited to, Calcinosis, Raynaud's, Esophagus, Sclerodactyly, and
Telangiectasia (CREST), limited systemic scleroderma, and diffuse
systemic scleroderma. Systemic scleroderma is also known as
systemic sclerosis (SSc). It may also be referred to as Progressive
Systemic Sclerosis (PSSc), or Familial Progressive Systemic
Sclerosis (FPSSc). Systemic sclerosis is a multisystem disorder
characterized by the presence of connective tissue sclerosis,
vascular abnormalities concerning small-sized arteries and the
microcirculation, and autoimmune changes.
[0094] The type of systemic scleroderma known as CREST is not
characterized by any skin tightening. CREST is characterized by
Calcinosis (calcium deposits), usually in the fingers; Raynaud's;
loss of muscle control of the Esophagus, which can cause difficulty
swallowing; Sclerodactyly, a tapering deformity of the bones of the
fingers; and Telangiectasia, small red spots on the skin of the
fingers, face, or inside of the mouth. Typically two of these
symptoms is sufficient for diagnosis of CREST. CREST may occur
alone, or in combination with any other form of Scleroderma or with
other autoimmune diseases.
[0095] Limited Scleroderma is characterized by tight skin limited
to the fingers, along with either pitting digital ulcers (secondary
to Raynaud's) and/or lung fibrosis. The skin of the face and neck
may also be involved in limited scleroderma.
[0096] Diffuse Scleroderma is diagnosed whenever there is proximal
tight skin. Proximal means located closest to the reference point.
Proximal tight skin can be skin tightness above the wrists or above
the elbows. Typically, a patient with skin tightness only between
their elbows and their wrists will receive a diagnosis of either
diffuse or limited systemic Scleroderma, depending on which meaning
of proximal the diagnosing clinician uses. These tests are examples
of tests that can be used in conjunction with the compositions and
methods described herein to check for abnormalities that might
exist (i.e., identify patients or patient populations in need of
treatment) or to monitor side effects of drugs and check
progress.
[0097] Activity of Autoimmune Diseases or Disorders
[0098] According to certain aspects, the patient or patient
population being treated with B10 cell compositions described
herein can have an autoimmune disease or disorder with a certain
activity. The activity of an autoimmune disease or disorder can be
measured by assessing multiple factors, such as, but not limited to
those described above for diagnosis of autoimmune diseases and
disorders. Although the above-described factors are presented in
the context of certain autoimmune diseases, one or more of these
factors can be used to determine the activity of other autoimmune
diseases or disorders. Methods for determining activity of an
autoimmune disease or disorder in a patient in relation to a scale
of activity are well known in the art and can be used in connection
with the pharmaceutical compositions and methods described
herein.
[0099] For example, the American College of Rheumatologists Score
(ACR score) can be used to determine the activity of rheumatoid
arthritis of a patient or a patient population. According to this
method, patients are given a score that correlates to improvement.
For example, patients with a 20% improvement in factors defined by
the ACR would be given an ACR20 score. This and other scoring
methods may be used in combination with the methods of assessing
B10 cell function described herein.
[0100] For certain other autoimmune diseases or disorders, there
are several accepted methods that can be used in conjunction with
the methods provided here to determine activity of an autoimmune
disease or disorder. For example, SLE at several disease assessment
scales, including, but not limited to, British Isle Lupus
Assessment Group (BILAG), Systemic Lupus Erythematosus Disease
Activity Index (SLEDI), Modified SLEDI, and Systemic Lupus Activity
measure (SLAM). In general, a high activity of an autoimmune
disease or disorder would be one which scores in the upper half
(e.g., greater severity of disease activity) of one or more of the
above scales and a low activity of an autoimmune disease or
disorder would be one which scores in the lower half (e.g., less
severity of disease activity) of one or more of the above
scales.
Inflammatory and Allergic Diseases
[0101] Any type of inflammatory disease can be treated in
accordance with the methods described herein. Non-limiting examples
of inflammatory diseases include, but are not limited to, asthma,
encephilitis, inflammatory bowel disease, chronic obstructive
pulmonary disease (COPD), allergic disorders, septic shock,
pulmonary fibrosis, undifferentiated spondyloarthropathy,
undifferentiated arthropathy, arthritis, inflammatory osteolysis,
and chronic inflammation resulting from chronic viral or bacterial
infections.
[0102] The methods of the invention encompass therapies that are
aimed at treating diseases associated with a helper T (Th)
1-mediated inflammatory response but not diseases associated with a
Th2-mediated inflammatory response. In an alternative aspect of
this embodiment, the methods of the invention encompass therapies
that are aimed at treating diseases associated with a Th2-mediated
inflammatory response but not diseases associated with a
Th1-mediated inflammatory response.
Transplantation
[0103] IL-10 is capable of inhibiting ischemia/reperfusion injury
(Deng et al., 2001, Kidney Int. 60:2118-28), graft-versus-host
disease, and transplant-related mortality (Baker et al., 1999, Bone
Marrow Transplant 23:1123-9; Holler et al., 2000, Bone Marrow
Transplant 25:237-41). As such, one embodiment of the present
invention involves treating transplant-associated
diseases/conditions by increasing the level of IL-10 in a patient
in need thereof.
[0104] In one embodiment, the levels of endogenous IL-10 are
increased in a subject receiving an organ transplant by
administration of a B10 cell subset such as B10 cells made by the
methods described herein. In one aspect of this embodiment, the B10
cell population is isolated from the patient themselves, i.e., the
subject is the donor. In another aspect of this embodiment, the B10
cell population is isolated from a donor that is not the subject.
The donor of the B10 cells may be the same as the organ donor. In
another embodiment, the B10 cell population is pooled from several
donors.
[0105] According to certain aspects of the invention, the treatment
regimen and dose used with the compositions and methods of the
invention is chosen based on a number of factors including, for
example, clinical manifestation that place a patient at risk for
developing humoral or cellular rejection, or clinical evidence that
such a rejection is developing. The terms "humoral" and
"antibody-mediated" are used interchangeably herein. The criteria
for assessing the risk that a patient will develop humoral or
cellular rejection are established according to the knowledge and
skill in the art. In one embodiment, a positive complement
dependent cytotoxicity or anti-globulin enhanced
complement-dependent cytotoxicity crossmatch indicates that a
patient is at high risk for humoral rejection. In one embodiment, a
positive crossmatch or a prior positive complement dependent
cytotoxicity or anti-globulin enhanced complement dependent
cytotoxicity crossmatch indicates that a patient is at an
intermediate risk for humoral rejection. In one embodiment, a
negative crossmatch indicates that a patient is at a low risk for
humoral rejection. Similarly, there are established criteria known
to those of skill in the art for establishing risk for cellular
transplant rejection.
[0106] In another embodiment, a transplant recipient in need of
prophylaxis against graft rejection may be identified as a patient
or patient population having detectable circulating anti-HLA
alloantibodies prior to transplantation. In another example, the
patient or patient population is identified as having panel
reactive antibodies prior to transplantation. The presence of
detectable circulating anti-HLA alloantibodies in a transplant
recipient post-transplantation can also be used to identify the
patient or patient population in need of treatment for humoral or
cellular rejection according to the invention. The patient or
patient population in need of treatment for humoral or cellular
rejection can also be identified according to other clinical
criteria that indicate that a transplant recipient is at risk for
developing humoral or cellular rejection or has already developed
humoral or cellular rejection. For example, a transplant recipient
in need of treatment of rejection may be identified as a patient or
population in an early stage of humoral rejection, such as a latent
humoral response characterized by circulating anti-donor
alloantibodies. An early stage of humoral rejection may also be a
silent reaction characterized by circulating anti-donor
alloantibodies and C4d deposition, or a subclinical rejection
characterized by circulating anti-donor alloantibodies, C4d
deposition, and tissue pathology. In later stages, the recipient is
identified as a patient or patient population presenting with
clinical indications of humoral or cellular rejection characterized
according to the knowledge and skill in the art, for example, by
circulating anti-donor alloantibodies, C4d deposition, tissue
pathology and/or inflammatory cell infiltrates, and graft
dysfunction.
[0107] The present invention provides compositions, therapeutic
formulations, methods and regimens effective to reduce the
incidence, severity, or duration of graft-versus-host disease
(GVHD), or a humoral or cellular rejection episode. In certain
embodiments, the compositions and methods of the invention are
effective to attenuate the host response to ischemic repefusion
injury of a solid tissue or organ graft. In a preferred embodiment,
the B10 effector cell compositions and methods of the invention are
effective to prolong survival of a graft in a transplant
recipient.
[0108] The present invention encompasses grafts that are
autologous, allogeneic, or xenogeneic to the recipient. The types
of grafts encompassed by the invention include tissue and organ
grafts, including but not limited to, bone marrow grafts,
peripheral stem cell grafts, skin grafts, arterial and venous
grafts, pancreatic islet cell grafts, organ transplants of the
kidney, liver, lung, pancreas, thyroid, and heart, and composite
tissue grafts involving tissues from multiple organ systems,
including but not limited to digits, limbs, regions of the body,
and facial tissues. The terms "graft" and "transplant" are used
interchangeably herein. In one embodiment, the autologous graft is
a bone marrow graft, an arterial graft, a venous graft or a skin
graft. In one embodiment, the allograft is a bone marrow graft, a
corneal graft, a kidney transplant, a pancreatic islet cell
transplant, or a combined transplant of a kidney and pancreas. In
one embodiment, the graft is a xenograft, preferably wherein the
donor, is a pig. The compositions and methods of the present
invention may also be used to suppress a deleterious immune
response to a non-biological graft or implant, including but not
limited to an artificial joint, a stent, or a pacemaker device.
[0109] The B10 effector cell compositions, and methods of the
invention can be used to treat or prevent GVHD, or humoral or
cellular rejection without regard to the particular indications
initially giving rise to the need for the transplant or the
particular type of tissue transplanted. However, the indications
that gave rise to the need for a transplant and the type of tissue
transplanted can provide a basis for a comprehensive therapeutic
regimen for the treatment or prevention of GVHD and graft
rejection, which comprehensive regimen comprises the B10 effector
cell compositions and methods of the invention.
[0110] Therapeutic formulations and regimens of the present
invention are described elsewhere for treating human subjects with
other conditions. Similarly, appropriate treatment regimens can be
determined by one of skill in the art for the particular patient or
patient population. In particular embodiments, the treatment
regimen is a pre-transplant conditioning regimen, a post-transplant
maintenance regimen, or post-transplant treatment regimen for acute
or chronic rejection. In certain embodiments, the particular
regimen is varied for a patient who is assessed as being at a high
or intermediate risk of developing a humoral or cellular immune
response, compared with the regimen for a patient who is assessed
as being at a low risk of developing a humoral or cellular response
directed against the transplant.
[0111] In certain embodiments, the particular regimen is varied
according to the stage of transplant rejection, with more
aggressive therapy being indicated for patients at later stages of
humoral or cellular rejection. The stages of humoral rejection may
be classified according to the knowledge and skill in the art. For
example, the stages of humoral rejection may be classified as one
of stages I to IV according to the following criteria: Stage I
Latent Response, characterized by circulating anti-donor
alloantibodies, especially anti-HLA antibodies; Stage II Silent
Reaction, characterized by circulating anti-donor alloantibodies,
especially anti-HLA antibodies, and C4d deposition, but without
histologic changes or graft dysfunction; Stage III Subclinical
Rejection: characterized by circulating anti-donor alloantibodies,
especially anti-HLA antibodies, C4d deposition, and tissue
pathology, but without graft dysfunction; Stage IV Humoral
Rejection: characterized by circulating anti-donor alloantibodies,
especially anti-HLA antibodies, C4d deposition, tissue pathology,
and graft dysfunction. Similarly, criteria for cellular rejection
are known to those practicing in the art.
[0112] Dose response curves can be generated using standard
protocols in the art in order to determine the effective amount of
the compositions of the invention for use in a particular regimen,
for example, in conditioning regimens prior to transplantation, and
in post-transplantation regimens for prophylaxis and treatment of
GVHD, or humoral or cellular rejection. In general, patients at
high risk for developing humoral or cellular rejection and those
already exhibiting one or more clinical indicators of rejection
will require higher doses and/or more frequent doses which may be
administered over longer periods of time in comparison to patients
who are not at high risk or who do not exhibit any indications of
active rejection.
[0113] The B10 effector cell compositions and methods of the
invention can be practiced to treat or prevent GVHD, or humoral or
cellular rejection, either alone or in combination with other
therapeutic agents or treatment regimens. Other therapeutic
regimens for the treatment or prevention of GVHD, or humoral or
cellular rejection may comprise, for example, one or more of
anti-lymphocyte therapy, steroid therapy, antibody depletion
therapy, immunosuppression therapy, and plasmapheresis.
Anti-lymphocyte therapy may comprise the administration to the
transplant recipient of anti-thymocyte globulins, also referred to
as thymoglobulin. Anti-lymphocyte therapy may also comprise the
administration of one or more monoclonal antibodies directed
against T cell and including B cell surface antigens. Examples of
such antibodies include, without limitation, OKT3.TM.
(muromonab-CD3), CAMPATH.TM.-1H (alemtuzumab), CAMPATHT.TM.-1G,
CAMPATH.TM.-1M, SIMULECT.TM. (basiliximab), and ZENAPAX.TM.
(daclizumab).
[0114] Steroid therapy may comprise administration to the
transplant recipient of one or more steroids selected from the
group consisting of cortisol, prednisone, methyl prednisolone,
dexamethazone, and indomethacin. Preferably, one or more of the
steroids are corticosteroids, including without limitation,
cortisol, prednisone, and methylprednisolone.
[0115] Antibody depletion therapy may include, for example,
administration to the transplant recipient of intravenous
immunoglobulin. Antibody depletion therapy may also comprise
immunoadsorption therapy applied to the graft ex vivo, prior to
transplantation. Immunoadsorption may be accomplished using any
suitable technique, for example, protein A affinity, or antibody
based affinity techniques using antibodies directed against T cell
or B cell surface markers such as anti-CD3 antibodies.
[0116] Immunosuppression therapy may comprise the administration of
one or more immunosuppressive agents such as inhibitors of cytokine
transcription (e.g., cyclosporin A, tacrolimus), nucleotide
synthesis (e.g., azathiopurine, mycophenolate mofetil), growth
factor signal transduction (e.g., sirolimus, rapamycin), and the T
cell IL-2 receptor (e.g., daclizumab, basiliximab). In a particular
embodiment, an immunosuppressant agent used in combination with the
compositions and methods of the invention includes one or more of
the following: adriamycin, azathiopurine, busulfan,
cyclophosphamide, cyclosporin A ("CyA"), cytoxin, fludarabine,
5-fluorouracil, methotrexate, mycophenolate mofetil (MOFETIL),
nonsteroidal anti-inflammatories (NSAIDs), rapamycin, and
tacrolimus (FK506). Immunosuppressive agents may also comprise
inhibitors of complement, for example, soluble complement
receptor-1, anti-05 antibody, or a small molecule inhibitor of Cls,
for example as described in Buerke et al. (J. Immunol., 167:5375-80
(2001). In one embodiment, the compositions and methods of the
invention are used in combination with one or more therapeutic
regimens for suppressing humoral or cellular rejection, including,
without limitation, tacrolimus and mycophenolate mofetil therapy,
immunoadsorption, intravenous immunoglobulin therapy, and
plasmapheresis.
[0117] Diagnosis and Clinical Criteria
[0118] The present invention provides antibodies, compositions and
methods for treating and preventing GVHD, and humoral or cellular
rejection in human transplant recipients. The compositions and
methods of the invention can be used regardless of the particular
indications that gave rise to the need for a transplant. Similarly,
the use of the compositions and methods of the invention for the
treatment and prevention of GVHD, and humoral or cellular rejection
is not limited by the particular type of tissue which is intended
for transplantation or which has been transplanted.
[0119] In one embodiment, the invention provides compositions and
methods for the prevention of humoral or cellular rejection in a
human transplant recipient wherein the transplant recipient is
identified as a patient or patient population at increased risk for
developing humoral or cellular rejection. Such patients may also be
referred to as "sensitized." Criteria for the identification of
sensitized patients are known to skilled practitioners. Such
criteria may include, for example, patients having detectable
levels of circulating antibodies against HLA antigens, e.g.,
anti-HLA alloantibodies. Such criteria may also include patients
who have undergone previous transplantations, a pregnancy, or
multiple blood transfusions. Patients who are at an increased risk
for humoral rejection also include those having imperfect
donor-recipient HLA matching, and those transplants that are
ABO-incompatible. Sensitized individuals are preferred candidates
for pretreatment or conditioning prior to transplantation.
Sensitized individuals are also preferred candidates for
post-transplantation maintenance regimens for the prevention of
humoral and cellular rejection.
[0120] In one embodiment, the B10 cell compositions and methods of
the invention comprise or are used in combination with a
therapeutic regimen for the treatment of an acute or chronic
rejection. In particular embodiments, the rejection is
characterized as Stage I, Stage II, Stage III, or Stage IV humoral
or cellular rejection.
[0121] In one embodiment, the B10 cell compositions and methods of
the invention comprise or are used in combination with a
therapeutic regimen for the treatment of an early stage humoral
rejection. In particular embodiments, the early stage humoral
rejection is Stage I, II, or III rejection. Clinical indications of
an early stage humoral rejection are determined according to the
knowledge and skill in the art and may include, for example, the
development in the patient of circulating donor-specific anti-HLA
antibodies, the presence of complement markers of antibody activity
such as C4d and C3d deposits in graft biopsies, and the presence of
anti-HLA antibodies in graft biopsies. Other indicators of an early
stage humoral rejection are known to the skilled practitioner and
may include, for example, the development of anti-endothelial
antibodies, especially anti-vimentin antibodies, and the
development of nonclassical MHC class I-related chain A (MICA)
alloantibodies. In one embodiment, the compositions and methods of
the invention comprise or are used in combination with a
therapeutic regimen for the treatment of humoral or cellular
rejection characterized in part by graft dysfunction. In particular
embodiments, the patient or patient population in need of treatment
for humoral or cellular rejection is identified according to
criteria known in the art for graft dysfunction. Examples of such
criteria for particular types of grafts are provided in the
sections that follow. In other embodiments, the patient or patient
population in need of treatment for humoral or cellular rejection
is identified according to other criteria that are particular to
the type of tissue graft, such as histological criteria. Examples
of such criteria are also provided in the sections that follow.
[0122] Bone Marrow Transplants
[0123] The compositions and methods of the invention are useful for
treating or preventing GVHD, and humoral or cellular rejection in a
bone marrow transplant recipient. In one embodiment, the
compositions and methods of the invention comprise or are used in
combination with a pre-transplant conditioning regimen. The graft
may be from any suitable source, for example, cord blood stem
cells, peripheral blood stem cells, or a bone marrow harvest.
Peripheral blood stem cells may be harvested from donor blood
following a suitable conditioning regimen. Suitable regimens are
known in the art and may include, for example, administration of
one or more of the following to the donor prior to harvesting the
donor blood: NEUPOGEN, cytokines such as GM-CSF, low dose
chemotherapeutic regimens, and chemokine therapy. The graft may be
either allogeneic or autologous to the transplant recipient. The
graft may also be a xenograft.
[0124] The compositions and methods of the invention are useful in
a number of contexts in which there is a hematopoietic indication
for bone marrow transplantation. In one embodiment, an autologous
bone marrow graft is indicated for a B cell leukemia or lymphoma,
preferably acute lymphoblastic leukemia ("ALL") or non-Hodgkins
lymphoma. In another embodiment, the graft is an allogeneic graft
and the B10 effector cell compositions and methods of the invention
are used for treating graft recipients as prophylaxis against
GVHD.
[0125] In one embodiment, the indication is a B cell associated
autoimmune condition and the compositions and methods of the
invention are used as therapy conditioning regimens. In one
embodiment, the compositions of the invention are administered in
combination with a chemotherapy or radiation therapy regimen, which
regimen comprises a lower dose of one or more chemotherapeutic
agents, or a lower dose of radiation, than the dose that is
administered in the absence of the compositions of the invention.
In one embodiment, the patient receives an autologous bone marrow
graft subsequent to chemotherapy or radiation therapy, wherein the
graft recipient is subsequently treated using the compositions and
methods described herein. A patient or patient population in need
of, or likely to benefit from, a bone marrow transplant is
identified according to the knowledge and skill in the art.
Examples of patients that may be candidates for bone marrow
transplantation include patients who have undergone chemotherapy or
radiation therapy for the treatment of a cancer or an autoimmune
disease or disorder, and patients who are unable to clear a viral
infection residing in cells of the immune system.
[0126] Liver Transplants
[0127] The compositions and methods of the invention are useful for
treating or preventing GVHD, and humoral or cellular rejection in a
liver transplant recipient. In particular embodiments, the
rejection is an acute or a chronic refection. In one embodiment,
the compositions and methods of the invention are used for the
prevention of GVHD, and humoral or cellular rejection in a liver
transplant recipient. In one embodiment, the compositions and
methods of the invention comprise or are used in combination with a
pre-transplant conditioning regimen. The liver transplant may be
from any suitable source as determined according to the knowledge
and skill in the art. In one embodiment, the liver is an
HLA-matched allogeneic graft. In another embodiment, the liver is a
xenograft, preferably from a pig donor. In one embodiment, the
liver is used ex vivo to filter the patient's blood, e.g.,
extracorporeal perfusion. Extracorporeal perfusion is a form of
liver dialysis in which the patient is surgically connected to a
liver maintained outside the body. This procedure is sometimes
referred to as "bioartificial liver." In accordance with this
embodiment, the compositions and methods of the invention are used
to prevent the development of antibodies and sensitized lymphocytes
against liver antigens which may contaminate the patient's blood.
In one embodiment, the compositions and methods of the invention
comprise an improved therapeutic regimen for the treatment and
prevention of GVHD, and humoral or cellular rejection. In a
particular embodiment, the compositions and methods of the
invention comprise an improved therapeutic regimen, wherein the
improvement lies in a decreased incidence and/or severity of
complications associated with traditional immunosuppressive agents.
In one embodiment, the incidence and/or severity of nephrotoxicity,
hepatotoxicity, and hirsutism is reduced compared with traditional
regimens relying on cyclosporinA or other calcinuerin inhibitors.
In one embodiment, the incidence and/or severity of obesity,
osteodystrophy, diabetes mellitus and susceptibility to bacterial
and viral infections is reduced compared with traditional regimens
relying on corticosteroids. In a preferred embodiment, the
compositions and methods of the invention are used in combination
with lower doses of one or more traditional immunosuppressive
agents than the doses that are used in the absence of
anti-lymphocyte antibody therapy. Preferably, the lower doses
result in a decreased incidence and/or severity of one or more
complications associated with the one or more traditional
immunosuppressive agents.
[0128] A patient or patient population in need of, or likely to
benefit from, a liver transplant is identified according to the
knowledge and skill in the art. Examples of patients that may be
candidates for liver transplantation include persons having one or
more of the following conditions, diseases, or disorders: acute
liver failure, amyloidosis, bilirubin excretion disorders, biliary
atresia, Budd-Chiari syndrome, chronic active autoimmune hepatitis,
cirrhosis (either associated with viral hepatitis including
hepatitis B and hepatitis C, alcoholic cirrhosis, or primary
biliary cirrhosis), cholangitis, congenital factor VIII or IX
disorder, copper metabolism disorders, cystic fibrosis,
glycogenesis, hypercholesterolemia, lipidoses,
mucopolysaccharidosis, primary sclerosing cholangitis, porphyrin
metabolism disorders, purine and pyrimidine metabolism disorders,
and primary benign and malignant neoplasms, especially of the liver
and intrahepatic bile ducts, biliary system, biliary passages, or
digestive system.
[0129] The clinical criteria for the identification of a patient or
patient population in need of, or likely to benefit from, a liver
transplant can be determined according to the knowledge and skill
in the art. Such criteria may include, for example, one or more of
the following symptoms: fatigue, weight loss, upper abdominal pain,
purities, jaundice, liver enlargement, discolored urine, elevated
alkaline phosphatase, and gamma glutamylpeptidase activity,
elevated bilirubin levels, decreased serum albumin, elevated
liver-specific enzymes, low bile production, increased blood urea
nitrogen, increased creatinine and/or presence of anti-neutrophil
cytoplasmic antibodies (ANCA) titers, recurrent variceal
hemorrhage, intractable ascites, spontaneous bacterial peritonitis,
refractory encephalopathy, severe jaundice, exacerbated synthetic
dysfunction, sudden physiologic deterioration, and fulminant
hepatic failure.
[0130] Kidney (Renal) Transplants
[0131] The compositions and methods of the invention are useful for
treating or preventing GVHD, and humoral or cellular rejection in a
renal transplant recipient. As used herein, the term "renal
transplant" encompasses the transplant of a kidney and the combined
transplant of a kidney and a pancreas. In particular embodiments,
the rejection is characterized as acute rejection or chronic
rejection.
[0132] In one embodiment, the compositions and methods of the
invention comprise or are used in combination with a pre-transplant
conditioning regimen. In one embodiment, a single dose of one or
more of the compositions of the present invention is effective in
the patient or patient population. In another embodiment, multiple
doses of one or more of the compositions of the invention are
effective in the patient or patient population. In one embodiment,
a single dose of one or more of the compositions of the present
invention is administered in combination with one or more
immunosuppressive agents and is effective in the patient or patient
population.
[0133] In certain embodiments, the compositions and methods of the
invention are for treating or preventing GVHD and graft rejection
in a patient having received a renal transplant. In one embodiment,
the patient has not yet exhibited clinical signs of rejection. In a
related embodiment, the compositions and methods of the invention
comprise or are used in combination with a maintenance regimen for
the prevention of graft rejection in the transplant recipient. In
one embodiment, the compositions and methods of the invention are
for the treatment of subclinical humoral rejection. In a related
embodiment, the patient or patient population in need of treatment
for a subclinical humoral rejection is indicated by the detection
of Cd4 deposition or cellular infiltration in a biopsy from the
graft, or by the detection of circulating anti-HLA antibodies. In
one embodiment, the compositions and methods of the invention are
for the treatment of subclinical cellular rejection.
[0134] In one embodiment, the compositions and methods of the
invention comprise or are used in combination with a therapeutic
regimen for the treatment of an acute or chronic rejection episode
in a transplant recipient. In one embodiment, the patient or
patient population in need of treatment for an acute or chronic
rejection episode is identified by the detection of one or more
clinical indicators of rejection. In specific embodiments, the one
or more clinical indicators of rejection are detected one to six
weeks post-transplantation. In one embodiment, the one or more
clinical indicators of rejection are detected 6, 12, 18, 24, 36,
48, or 60 months post-transplantation. In a preferred embodiment,
the acute rejection is biopsy-confirmed acute humoral or cellular
rejection.
[0135] In one embodiment, one or more of the compositions of the
invention comprise a therapeutic regimen for the treatment of acute
rejection. In a particular embodiment, the therapeutic regimen
further comprises one or more of the following: plasmapheresis,
tacrolimus/mycophenolate, intravenous immunoglobulin, and
immunoadsorption with protein A. In one embodiment, the patient has
been on an immunosuppressive protocol prior to the development of
the rejection. In a particular embodiment, the immunosuppressive
protocol includes one or more of cyclosporine, azathioprine, and
steroid therapy.
[0136] Clinical indicators of acute humoral and cellular rejection
are known in the art and include, for example, a sudden severe
deterioration of renal function, the development of oliguria, and
compromised renal perfusion. Additional indicators include, for
example, inflammatory cells in peritubular capillaries on biopsy
and circulating donor-specific alloantibodies. In one embodiment,
the patient presents with one or more of the following diagnostic
criteria for a humoral rejection of a renal allograft: (1)
morphological evidence of acute tissue injury; (2) evidence of
antibody action, such as C4d deposits or immunoglobulin and
complement in arterial fibrinoid necrosis; and (3) detectable
circulating antibodies against donor HLA antigens or donor
endothelial antigens. In one embodiment, the patient presents with
all three of the above diagnostic criteria.
[0137] In one embodiment, the patient presents with one or more of
the diagnostic criteria for acute humoral or cellular rejection and
the compositions of the present invention are used in combination
with one or more of the following immunosuppressive agents to treat
acute rejection: intravenous immunoglobulin, anti-thymocyte
globulins, mycophenolate mofetil, or tacrolimus. In another
embodiment, the compositions of the invention are used in
combination with one or more immunosuppressive agents and a
procedure for the removal of alloantibodies from the patient, such
as plasmapheresis or immunoadsorption.
[0138] In one embodiment, the compositions and methods of the
invention comprise or are used in combination with a therapeutic
regimen for the treatment of chronic renal allograft rejection. In
one embodiment, one or more of the compositions of the invention
are used alone or in combination with one or more immunosuppressive
agents, including for example, monoclonal antibodies, tacrolimus,
sirolimus, and mizoribin. In a preferred embodiment, one or more of
B10 effector cell compositions of the invention are used in
combination with tacrolimus, mycophenolate, or other appropriate
therapeutics.
[0139] Clinical indicators of chronic rejection in the kidneys are
known in the art and may include, for example, arterial intiamal
fibrosis with intimal mononuclear cells (chronic allograft
vasculopathy), duplication of the glomerular basement membranes
(chronic allograft glomerulopathy), lamination of the peritubular
basement membrane, C4d deposition in peritubular capillaries,
inflammatory cell infiltrates and immunopathology, and detectable
circulating donor HLA-reactive antibodies. In a preferred
embodiment, the compositions and methods of the invention comprise
or are used in combination with a therapeutic regimen to treat
chronic rejection before graft lesions develop.
[0140] In another embodiment, the patient or patient population in
need of treatment is identified as having one or more clinical
indicators of transplant glomerulopathy. In a related embodiment,
the compositions of the invention comprise or are used in
combination with a therapeutic regimen comprising one or more
therapeutic agents. In a preferred embodiment, the therapeutic
regimen is effective to stabilize renal function and inhibit graft
rejection. In a particular embodiment, the one or more therapeutic
agents include angiotensin converting enzyme (ACE) inhibitors
and/or receptor antagonists, intra-venous immunoglobulin,
anti-thymocyte globulins, mycophenolate mofetil, or tacrolimus.
Preferably, the B10 effector cells of the invention are used in
combination with mycophenolate mofetil and tacrolimus, with or
without other therapeutic agents. Plasmapheresis and other
treatments may also be used as part of the therapeutic regimen.
[0141] A patient or patient population in need of, or likely to
benefit from, a renal transplant is identified according to the
knowledge and skill in the art. Examples of patients that may be
candidates for renal transplantation include patients diagnosed
with amyloidosis, diabetes (type I or type 11), glomerular disease
(e.g., glomerulonephritis), gout, hemolytic uremic syndrome, HIV,
hereditary kidney disease (e.g., polycystic kidney disease,
congenital obstructive uropathy, cystinosis, or prune bell
syndrome), other kidney disease (e.g., acquired obstructive
nephropathy, acute tubular necrosis, acute interstitial nephritis),
rheumatoid arthritis, systemic lupus erythematosus, or sickle cell
anemia. Other candidates for renal transplant include patients
having insulin deficiency, high blood pressure, severe injury or
burns, major surgery, heart disease or heart attack, liver disease
or liver failure, vascular disease (e.g., progressive systemic
sclerosis, renal artery thrombosis, scleroderma), vesicoureteral
reflux, and certain cancers (e.g., incidental carcinoma, lymphoma,
multiple myeloma, renal cell carcinoma, Wilms tumor). Other
candidates for renal transplant may include, for example, heroin
users, persons who have rejected a previous kidney or pancreas
graft, and persons undergoing a therapeutic regimen comprising
antibiotics, cyclosporin, or chemotherapy. The clinical criteria
for the identification of a patient or patient population in need
of, or likely to benefit from, a kidney transplant can be
determined according to the knowledge and skill in the art. Such
criteria may include, for example, one or more of the following:
urinary problems, bleeding, easy bruising, fatigue, confusion,
nausea and vomiting, loss of appetite, pale skin (from anemia),
pain in the muscles, joints, flanks, and chest, bone pain or
fractures, and itching.
[0142] Cardiac Transplants
[0143] The compositions and methods of the invention are useful for
treating or preventing GVHD, and humoral or cellular rejection in a
cardiac transplant recipient. In particular embodiments, the
rejection is acute or a chronic rejection. In one embodiment, the
compositions and methods of the invention comprise or are used in
combination with a pre- or post-transplant conditioning
regimen.
[0144] In certain embodiments, the compositions and methods of the
invention comprise or are used in combination with a therapeutic
regimen for the treatment of acute humoral or cellular rejection in
a cardiac transplant recipient. In a particular embodiment, the
therapeutic regimen further comprises one or more of the following:
plasmapheresis, intravenous immunoglobulin, and antibody therapy.
The patient or patient population in need of treatment for an acute
humoral rejection is identified by the detection of one or more of
the clinical indications of acute humoral rejection. Examples of
clinical indicators of acute humoral rejection may include one or
more of the following: hemodynamic dysfunction, defined by shock,
hypotension, decreased cardiac output, and a rise in capillary
wedge or pulmonary artery pressure. In a particular embodiment, the
acute humoral rejection is diagnosed within 6, 12, 18, 24, 36, 48,
or 60 months post-transplantation.
[0145] In one embodiment, the compositions and methods of the
invention comprise or are used in combination with a therapeutic
regimen for the prevention of humoral or cellular rejection in a
cardiac transplant recipient. In one embodiment, the transplant
recipient in need of prophylaxis against rejection is identified as
a patient or patient population having one or more of the following
risk factors: female sex, cytomegalovirus seropositivity, elevated
response to panel reactive antibodies, positive pre- and/or
post-transplant crossmatch, and pre-sensitization with
immunosuppressive agents.
[0146] In one embodiment, the compositions and methods of the
invention are for the treatment or prevention of graft
deterioration in a heart transplant recipient. In one embodiment,
the transplant recipient in need of treatment for, or prophylaxis
against, graft deterioration is identified as a patient or patient
population having one or more of the following clinical indications
of humoral or cellular rejection: deposition of immunoglobulin,
C1q, C3, and/or C4d in capillaries, evidence of CD68-positive cells
within capillaries, and evidence of infiltration of the graft by
inflammatory cells upon biopsy. In one embodiment, the compositions
of the present invention are used in combination with one or more
of the following immunosuppressive agents to treat graft
deterioration in a heart transplant recipient: intravenous
immunoglobulin, anti-thymocyie globulins, monoclonal antibodies,
mycophenolate mofetil, or tacrolimus. In another embodiment, the
B10 effector cell compositions of the invention are used in
combination with one or more immunosuppressive agents and a
procedure for the removal of alloantibodies from the patient, such
as plasmapheresis or immunoadsorption.
[0147] In one embodiment, the compositions and methods of the
invention comprise or are used in combination with a therapeutic
regimen for the treatment of chronic cardiac rejection, preferably
chronic allograft vasculopathy, also referred to as transplant
coronary artery disease. In another embodiment, the compositions
and methods of the invention comprise or are used in combination
with a therapeutic regimen for the prevention of transplant
coronary artery disease in a patient or patient population at risk.
The criteria for identifying a patient or patient population at
risk of developing transplant coronary artery disease are known in
the art and may include, for example, patients having poorly
matched transplants, patients who develop circulating anti-HLA
antibodies, and patients who develop one or more clinical
indications of humoral or cellular rejection early after cardiac
transplant.
[0148] A patient or patient population in need of, or likely to
benefit from a heart transplant is identified according to the
knowledge and skill in the art. Examples of patients that may be
candidates for heart transplantation include those who have been
diagnosed with any of the following diseases and disorders:
coronary artery disease, cardiomyopathy (noninflammatory disease of
the heart), heart valve disease with congestive heart failure,
life-threatening abnormal heart rhythms that do not respond to
other therapy, idiopathic cardiomyopathy, ischemic cardiomyopathy,
dilated cardiomyopathy, ischemic cardiomyopathy, and congenital
heart disease for which no conventional therapy exists or for which
conventional therapy has failed.
[0149] The clinical criteria for the identification of a patient or
patient population in need of, or likely to benefit from, a heart
transplant can be determined according to the knowledge and skill
in the art. Such criteria may include, for example, one or more of
the following: ejection fraction less than 25%, intractable angina
or malignant cardiac arrhythmias unresponsive to conventional
therapy, and pulmonary vascular resistance of less than 2 Wood
units. In addition, the patient or patient population in need of a
heart transplant may be identified by performing a series of tests
according to the knowledge and skill in the art. Such tests
include, for example, resting and stress echocardiograms, EKG,
assay of blood creatinine levels, coronary arteriography, and
cardiopulmonary evaluation including right- and left-heart
catheterization.
[0150] Lung Transplant
[0151] The compositions and methods of the invention are useful for
treating or preventing GVHD, and humoral or cellular rejection in a
lung transplant recipient. In particular embodiments, the refection
is characterized as an acute or a chronic rejection. In one
embodiment, the compositions and methods of the invention comprise
or are used in combination with a pre-transplant conditioning
regimen. A patient or patient population in need of, or likely to
benefit from, a lung transplant is identified according to the
knowledge and skill in the art. Examples of patients that may be
candidates for lung transplantation include patients having one of
the following diseases or conditions: bronchiectasis, chronic
obstructive pulmonary disease, cystic fibrosis, Eisenmenger
syndrome or congenital heart disease with Eisenmenger syndrome.
emphysema, eosinophilic granuloma of the lung, or histiocytosis X,
inhalatiodbum trauma, lymphangioleiomyomatosis (LAM), primary
pulmonary hypertension, pulmonary fibrosis (scarring of the lung),
or sarcoidosis.
[0152] The clinical criteria for the identification of a patient or
patient population in need of, or likely to benefit from, a lung
transplant can be determined according to the knowledge and skill
in the art. Such criteria may include, for example, one or more of
the following: chronic obstructive pulmonary disease (COPD) and
alpha1-antitrypsin deficiency emphysema characterized by one or
more of the following indicators: postbronchodilator FEV1 of less
than 25% predicted, resting hypoxemia, i.e., Pa0.sub.2 of less than
55-60 mm Hg, hypercapnia. secondary pulmonary hypertension, a rapid
rate of decline in FEV1, or life-threatening exacerbations; cystic
fibrosis characterized by one or more of the following indicators:
postbronchodilator FEV1 of less than 30% predicted, resting
hypoxemia, hypercapnia, or increasing frequency and severity of
exacerbations; idiopathic pulmonary fibrosis characterized by one
or more of the following indicators: vital capacity (VC) and TLC of
less than 60-65% predicted, and resting hypoxemia; secondary
pulmonary hypertension characterized by clinical, radiographic, or
physiologic progression while on medical therapy; primary pulmonary
hypertension characterized by one or more of the following
indicators: NYHA functional class III or IV, mean right atrial
pressure of greater than 10 mm Hg, mean pulmonary arterial pressure
of greater than 50 mm Hg, cardiac index of less than 2.5
L/min/m.sup.2, and failure of therapy with long-term prostacyclin
infusion.
Treatment of Subjects Receiving Biologics
[0153] Methods of treating subjects receiving recombinant,
therapeutic or xenogeneic protein(s) are also provided. The methods
include administering a therapeutically effective amount of the B10
cells described herein to a subject in need of treatment for a
genetic, transplantation, allergy, inflammation, or autoimmune
disorder. In particular the B10 cells may be co-administered with a
biologic or other therapeutic to which a subject may develop or has
developed anti-drug antibodies.
[0154] As the number of biologic therapies that reach the clinics
continues to increase, there is an increasing appreciation that
recipients frequently develop immune responses to these drugs,
which has a potential clinical impact on drug efficacy. Immune
responses to biologics are generally monitored by detection and
characterization of anti-drug antibodies (ADA) and assessing ADA
associations with drug exposure, efficacy and safety. The detection
of ADA does not necessarily mean that there will be clinical
consequences. There are, however, an increasing number of examples
where ADA can challenge drug efficacy and patient safety.
[0155] Thus the B10 cell compositions may be used in combination
with (co-administration, provided before or after) a biologic
therapy to avoid production of ADA.
Assessing B10 Cell Function
[0156] Methods of assessing the B10 cell function in a subject are
also provided herein. The methods include harvesting B cells from a
subject as discussed above for the methods of expanding B cells ex
vivo and culturing the cells in the presence of a CD40 agonist and
IL-21. Any of the methods for expanding B cells described herein
may be utilized to assess B10 cell function in the subject. After
culturing with IL-21, the cells are then assayed to determine if
the cells are capable of producing IL-10. The percentage of cells
in the culture capable of making IL-10 and/or the amount of IL-10
produced by the cells may be determined. The determination may be
made either after culturing with IL-21 or after culture with
another stimulatory molecule or combination of molecules such as an
antigen or LPS. The determination of the percentage of cells
producing IL-10 or the amount of IL-10 being produced may be
determined by any method available to one of skill in the art.
[0157] The amount of IL-10 or percentage of cells producing IL-10
may be determined and compared to a control. Suitably the control
is a normal control comprising B cells from a healthy donor treated
similarly to the cells obtained from the subject. Alternatively the
control may be represented by a numeric range over which healthy
donor cells are expected to fall. The B10 cell function of the
subject may be normal, overactive or deficient as compared to a
healthy donor. If B10 cell function is not normal, the method may
be used to diagnose the subject or indicate that the subject either
has or is likely to have a disease or condition affecting B10 cell
function.
[0158] The following examples are meant only to be illustrative and
are not meant as limitations on the scope of the invention or of
the appended claims. All references cited herein are hereby
incorporated by reference in their entireties.
EXAMPLES
[0159] To identify signals that regulate B10 cells in vivo,
purified B cells were cultured with cytokines known to influence B
cell function. Stimulation with IL-21, but not IL-4, -6, -10, -12,
-23 or -27, induced 2.7- to 3.2-fold higher B10 cell frequencies
and 4.4- to 5.3-fold more IL-10 secretion (p<0.01) at 48 and 72
h, respectively, while interferon-.gamma. (IFN-.gamma.) or
transforming growth factor-.beta. (TGF-.beta.) reduced IL-10.sup.+
B cell frequencies by 56% (p<0.05; FIG. 1A). In fact, IL-21
induced B10 cells to produce IL-10 without a need for in vitro
stimulation (FIG. 5A) and induced B cell IL-10 secretion at levels
similar to lipopolysaccharide (LPS) stimulation (FIG. 1A). IL-21
also induced a 3-fold increase in IL-10.sup.+ B cells within the
spleen CD1d.sup.hiCD5.sup.+ B cell subset that is enriched for
B10pro and B10 cells, but it did not induce significant numbers of
IL-10.sup.+ B cells among the CD1d.sup.loCD5.sup.- subset (FIG.
1B). There was little if any detectable B cell division in the 48
or 72 h assays when the cells were cultured with cytokines alone.
Even when mitogens such as anti-IgM antibody or LPS were added to
induce B cell proliferation, there was still little proliferation
at 48 h, although B10 cells are the most proliferative cells at 72
h. IL-21 did not promote B10 cell survival, but instead accelerated
the apoptosis of non-B10 cells while B10 cells were predominantly
spared. The net result was that B10 cell numbers were
preferentially increased by IL-21 relative to other cytokines.
Consistent with this, IL-21 induces either B cell apoptosis or
differentiation in a context-dependent manner, driving the in vitro
differentiation and expansion of more completely activated B cells.
See Spolski, R. & Leonard, W. J. Interleukin-21: basic biology
and implications for cancer and autoimmunity. Annu Rev Immunol 26,
57-79 (2008) and Ozaki, K. et al. Regulation of B cell
differentiation and plasma cell generation by IL-21, a novel
inducer of Blimp-1 and Bcl-6. J. Immunol. 173, 5361-5371 (2004).
IL-21 is also known to be a potent inducer of T cell IL-10
production, and T cell-derived IL-21 plays multiple important roles
in B cell effector function. Both B10 and non-B10 cells expressed
cell surface IL-21 receptor (IL-21R) at similar levels (FIG. 1C).
Despite this, ex vivo B10 and B10+B10pro cell and
CD1d.sup.hiCD5.sup.+ B cell numbers were similar in
IL-21R-deficient (IL-21R.sup.-/-), wild type, MHC-II.sup.-/- and
CD40.sup.-/- mice (FIG. 5B-D). However, IL-21R expression was
required for B10 cell expansion following myelin oligodendrocyte
glycoprotein peptide (MOG.sub.35-55) immunizations to induce EAE
(FIG. 1D). Thus, IL-21R-generated signals induced B cell IL-10
secretion in vivo and in vitro and were required for B10 cell
expansion in vivo.
[0160] Whether B10 cells require IL-21 to induce their regulatory
function in vivo was determined by the adoptive transfer of
IL-21R.sup.-/- B cells into CD19.sup.-/- mice before the induction
of EAE by MOG.sub.35-55 immunization. Because CD19.sup.-/- mice are
B10 cell-deficient (FIG. 1d), their EAE disease severity is worse
(FIG. 2A). The adoptive transfer of wild type CD1d.sup.hiCD5.sup.+
B cells normalized EAE severity in CD19.sup.-/- mice. By contrast,
the transfer of CD1d.sup.hiCD5.sup.+ B cells from IL-10.sup.-/- or
IL-21R.sup.-/- mice or wild type CD1d.sup.loCD5.sup.- non-B10 cells
did not alter disease. Because CD4.sup.+ T cells are a major source
of IL-21, we determined whether cognate B10-T cell interactions
also controlled B10 cell-mediated suppression of EAE. The transfer
of CD1d.sup.hiCD5.sup.+ B cells from MHC-II.sup.-/- or CD40.sup.-/-
mice into CD19.sup.-/- mice before MOG immunizations did not reduce
EAE disease severity (FIG. 2A, bottom right two panels).
CD1d.sup.loCD5.sup.- B cells from IL-21R.sup.-/-, CD40.sup.-/- or
MHC-II.sup.-/- mice were also without effect. EAE is also
exacerbated in wild type mice depleted of mature B cells by CD20
mAb. However, transfer of CD1d.sup.hiCD5.sup.+ B cells from
CD20.sup.-/- mice but not MHC-II.sup.-/- CD20.sup.-/- mice
normalized disease severity in this model, and CD1d.sup.loCD5.sup.-
B cells from CD20.sup.-/- or MHC-II.sup.-/- CD20.sup.-/- mice were
without effect (FIG. 2B). Similarly, the adoptive transfer of in
vitro activated CD1d.sup.hiCD5.sup.+ B cells from wild type mice
significantly reduced EAE disease severity in wild type mice,
whereas activated MHC-II.sup.-/- CD1d.sup.hiCD5.sup.+ or wild type
CD1d.sup.loCD5.sup.- B cells had no effect (FIG. 2C). Thus,
regulatory B10 cell function required IL-10 expression, IL-21R
signaling, as well as CD40 and MHC-II interactions, thereby
potentially explaining antigen-specific B10 cell effector
function.
[0161] IL-10 produced by activated CD1d.sup.hiCD5.sup.+ B cells
inhibits antigen-specific CD4.sup.+ T cell IFN-.gamma. and
TNF-.alpha. expression in vitro. To determine whether cognate B10-T
cell interactions regulate antigen-specific T cell proliferation in
vivo, B10 cell function was assessed in MOG.sub.35-55-immunized
CD19.sup.-/- mice following the adoptive transfer of dye-labeled
CD4.sup.+ T cells from transgenic mice expressing antigen receptors
(TCR.sup.MOG) specific for MOG.sub.35-55 peptide. See Bettelli, E.
et al. Myelin oligodendrocyte glycoprotein-specific T cell receptor
transgenic mice develop spontaneous autoimmune optic neuritis. J.
Exp. Med. 197, 1073-1081 (2003). CD1d.sup.hiCD5.sup.+ B cells from
naive wild type mice significantly reduced TCR.sup.MOG CD4.sup.+ T
cell proliferation as measured by in vivo dye dilution (FIG. 3A).
CD1d.sup.hiCD5.sup.+ B cells obtained from mice with EAE were even
more potent inhibitors of T cell proliferation, while
CD1d.sup.loCD5.sup.- B cells from wild type mice or
CD1d.sup.hiCD5.sup.+ B cells from IL-10.sup.-/-, CD40.sup.-/-, or
MHC-II.sup.-/- mice were without effect. CD1d.sup.hiCD5.sup.+ B
cells from naive or antigen-experienced wild type mice also
significantly reduced TCR.sup.MOG CD4.sup.+ T cell IFN-.gamma. and
IL-17 production in MOG.sub.35-55-immunized CD19.sup.-/- mice,
while CD1d.sup.hiCD5.sup.+ B cells from IL-10.sup.-/-, CD40.sup.-/-
or MHC-II.sup.-/-mice did not (FIG. 3B). The ability of B10 cells
to inhibit T cell IL-17 production is particularly important since
pathogenic T.sub.H17 T cells induce EAE and can produce IL-21. The
majority of T follicular helper cells isolated from mice with
MOG.sub.35-55-induced EAE also express IL-21, and CD19.sup.-/- mice
have T follicular helper cells (FIG. 6). Thus, B10 and T cells may
require intimate interactions during reciprocal IL-10 and IL-21
production to optimally regulate antigen-specific disease (FIG.
3C).
[0162] Although T follicular helper cells are a likely source of
IL-21, there are currently no indications that B10 cells are
germinal center constituents and most data argue against this.
First, B10 cell BCRs are predominantly germline and contain modest
frequencies of IgV.sub.H and IgV.sub.L mutations. Maseda, D. et al.
Regulatory B10 cells differentiate into antibody-secreting cells
after transient IL-10 production in vivo. J. Immunol. 188,
1036-1048 (2012). Second, B10 cell numbers expand early during the
induction of EAE, prior to the generation of germinal centers.
Matsushita, T., Horikawa, M., Iwata, Y. & Tedder, T. F.
Regulatory B cells (B10 cells) and regulatory T cells have
independent roles in controlling EAE initiation and late-phase
immunopathogenesis. J. Immunol. 185, 2240-2252 (2010). Third, B10
cell GL-7 expression resembles spleen follicular B cells and not
GL-7.sup.high germinal center B cells. Matsushita, 2010.
Furthermore, a hallmark of transgenic mice with dramatically
expanded B10pro+B10 cell numbers is the absence of germinal centers
and little if any B cell isotype switching, even after
immunizations. Poe, J. C. et al. Amplified B lymphocyte CD40
signaling drives regulatory B10 cell expansion in mice. PLoS ONE 6,
e22464 (2011). B10 cells in these mice are also located throughout
both the marginal zone and follicular areas of the spleen.
[0163] To verify that T cell-derived IL-21 and CD40 signals drive
B10 cell expansion and IL-10 production, B cells were cultured
using conditions to promote mouse B10 cell expansion in vivo and B
cell expansion in vitro. See Poe, 2011 and Nojima, T. et al.
In-vitro derived germinal centre B cells differentially generate
memory B or plasma cells in vivo. Nature Comm. 2, 465 (2011). B
cells were cultured on monolayers of NIH-3T3 cells expressing the T
cell ligand for CD40 (CD154) and BLyS in the presence of IL-4 for 4
days to induce B10pro cell maturation into IL-10-competent B10
cells. The B cells were then cultured on fresh NIH-3T3-CD154/BLyS
cells with exogenous IL-21 for 5 days, which were all essential to
optimally expand B10 cells and induce IL-10 production (FIG. 4A).
After the 9 day culture period, B cell and B10 cell numbers were
increased by 25,000- and 4,000,000-fold, respectively, with 38% of
the B cells actively producing IL-10 (FIG. 4B). The vast majority
of IL-10.sup.+ B cells in the cultures expressed CD5 (FIG. 4C),
facilitating their purification and underscoring the dramatic
effect of IL-21 on B10 cell numbers in vitro.
[0164] In vitro-expanded CD5.sup.+ B10 cells retained their
regulatory function. The transfer of CD5.sup.+ B10 cells
dramatically reduced EAE disease severity in wild type mice, even
when given after the appearance of disease symptoms, while
CD5.sup.- B cells were without effect (FIG. 4D). Although the in
vitro expansion of B10 cells required both IL-21R and CD40 signals,
MHC-II expression was not required (FIG. 4E). However, in
vitro-expanded MHC-II.sup.-/- CD5.sup.+ B10 cells and IL-10.sup.-/-
CD5.sup.+ B cells did not regulate EAE disease severity (FIG. 4F),
further documenting a requirement for IL-10 and cognate
interactions in the regulation of T cell-mediated disease. B10
cells did not expand during in vitro cultures of B cells from
CD19.sup.-/- mice or MD4 transgenic mice that have a fixed BCR
specific for egg lysozyme (FIG. 4E), further underscoring the
importance of BCR specificity and signaling in B10 cell generation.
Otherwise, in vitro-expanded B10 effector cells were potent
regulators of both disease initiation and progression.
[0165] This study demonstrates that CD40 signals induce B10pro cell
acquisition of IL-10 competence with IL-21 driving B10 cell
expansion and effector cell generation. These critical checkpoints
in B10 cell development may lead to localized IL-10 production that
blunts antigen-specific T cell responses during cognate
interactions (FIG. 3C) without untoward immunosuppression.
Transient IL-10 production by B10 cells in vivo may further
restrict the effects of IL-10 secretion. B10 effector cells may
also regulate T cell responses to autoantigens in addition to MOG
once inflammation and tissue destruction are initiated by
MOG.sub.35-55 immunization. Since human and mouse B10 cells are
also potent regulators of macrophage and dendritic cell function, T
cell induction of B10 effector cells may also contribute to EAE
resolution by restraining monocyte and dendritic cell activation.
These collective results may explain in part why EAE is exacerbated
in the absence of IL-21 signaling. By contrast, TGF-.beta. and
IFN-.gamma. may counterbalance B10 cell expansion in vivo based on
the current in vitro findings (FIG. 1A). Regulatory T cells provide
an independent layer of regulation during EAE since their
expansion, accumulation in the central nervous system, and
suppressive activity are normal when B10 cells are absent. The in
vitro recapitulation of these collective signals induced a several
million-fold expansion of B10 cells and their functional maturation
into potent B10 effector cells that reversed established autoimmune
disease (FIG. 4). In addition to BCR specificity, MHC-II expression
remained an important checkpoint for B10 effector cell regulatory
function during EAE (FIG. 4F), as first described for regulatory
type II monocytes. Since autoimmunity has multigenic origins and
autoantigens vary between patients and disease, in vitro expansion
of the rare pool of human blood B10pro and B10 effector cells may
provide a potent future immunotherapy for individuals with severe
autoimmune disease.
[0166] Human B10 Cell Expansion In Vitro.
[0167] To determine whether IL-21 and CD40 signals drive human B10
cell expansion in vitro, purified blood B cells
(1.times.10.sup.6/ml) were cultured on confluent monolayers of
mitomycin C-treated NIH-3T3 cells expressing the mouse T cell
ligand for CD40 (mCD154) and human BLyS (hBLyS) in the presence of
human IL-4 (2 ng/ml) for 7 days to induce B10pro cell maturation
into IL-10-competent B10 cells. The B cells were then cultured on
fresh NIH-3T3-mCD154/hBLyS cell monolayers with exogenous human
IL-21 (10 ng/ml) for 5 days. NIH-3T3 cells expressing mouse CD154
were used for both the mouse and human studies because mouse CD154
binds human CD40 (Bossen et al. 2006 J. Biol. Chem.
281:13964-13971) and mouse CD154 can induce signals through both
mouse and human CD40 (Armitage et al. 1992 Nature 357:80-82 and
Yasui et al., 2002 Intl. Immunol. 14:319-329). By contrast, human
CD154 does not bind mouse CD40 (Bossen et al., 2006). Human BLyS
was used for both mouse and human B cell expansion because human
BLyS appears to bind both human and mouse receptors (BCMA, TACI and
BAFF-R) similarly (Bossen et al. 2006)). After the 12 day culture
period, B cell numbers increased by 130 (.+-.17)-fold, while B10
cell numbers were increased by 5-6,000-fold, with 13-16% of the B
cells expressing IL-10 following 5 h of stimulation with phorbol
ester, ionomycin and Brefeldin-A (FIG. 7). These results parallel
our early results with in vitro expansion of mouse B cells and B10
effector cells, and indicate that this culture system is
translatable to humans.
[0168] As occurred with our mouse studies, additional refinement of
the culture system and protocols will be required for maximal human
blood B cell and B10 effector cell expansion. These findings are
not unanticipated as human B cell subpopulations respond
differently to graded levels of CD40-CD154 interactions (Neron et
al. 2005 Immunology 116:454-463) and various forms of CD40 ligand
used for in vitro stimulation of human B cells, such as
membrane-associated CD154, soluble trimeric, dimeric or monomeric
CD154 proteins or anti-CD40 antibodies, produce distinct functional
responses in a wide range of B cell activities (Fanslow et al. 1994
Sem. Immunol. 6:267-278). Furthermore, human CD40 costimulation is
differentially affected by cytokines. For example, CD40 ligation in
the presence of IL-4 co-stimulates human B cells to secrete IgE and
IgG4, while CD40 ligation in the presence of IL-2 or IL-10 induces
human blood or tonsil B cells to secrete other Ig isotypes (IgM,
IgG1, IgG2, IgG3 and IgA).
[0169] Feeder Cell Supplemental Factors Involved in Ex Vivo B Cell
Expansion.
[0170] Our findings during in vitro expansion of mouse and human B
cells and B10 effector cells demonstrate that this culture system
is translatable to humans, but is not solely dependent on the
addition of exogenous IL-4 and IL-21, or feeder cell expression of
CD154 and BLyS. Each of these factors must be optimized for maximal
B cell and B10 cell expansion and different B cell subpopulations
respond differently to graded levels of CD4O-CD154 interactions
(Neron et al., 2005 Immunology 116:454-463). Furthermore, it is
anticipated that additional factors can be added to the cultures or
expressed by the feeder cells to further optimize B cell and B10
cell expansion.
[0171] Most important is that not all mouse NIH-3T3 (Swiss)
fibroblasts, mouse 3T3-Balb/c fibroblasts, or human EA Hy.926
endothelial cells (Li et al., 1998 J. Exp. Med. 188:1385-1390 and
Edgell et al., 1983 Proc. Natl. Acad. Sci., USA 80:3734-3737) are
equivalent. For example, CD154.sup.+ BLyS.sup.+ NIH-3T3 and
3T3-Balb/c fibroblasts were able to induce dramatic B cell
activation and proliferation, with the majority of activated B
cells adhering to the stromal cells and forming large grape-like
clusters. By contrast, EA Hy.926 endothelial cells were only able
to induce dramatic B cell activation and the activated B cells did
not adhere to the stromal cells. However, we subsequently
determined that EA Hy.926 cells did not express vascular cell
adhesion molecule 1 (VCAM-1), while both fibroblast cell lines
constitutively expressed VCAM-1 (Table 1; below). Importantly, we
have determined that B cell adhesion to stromal cells is required
for their initial activation and expansion in the culture system.
VCAM-1 is critical for molecular interactions between stromal cells
and B cell precursors that lead to B lymphohematopoiesis (Kincade
et al., 1989 Annu. Rev. Immunol. 7:111-143 and Kincade 1992 Semin
Immunol 3:379-390). Similarly, CD44 binding of hyaluronic acid and
potentially other molecules is required for B cell adherence to
bone marrow stromal cells and subsequent lymphohematopoiesis in
long term bone marrow cultures (Lesley et al. 1992 J. Exp. Med.
175:257-266.). Both NIH-3T3 and 3T3-Balb/c fibroblasts
constitutively express CD44 (Table 1). Thus, effective stromal
cells must express appropriate cell surface molecules and/or
provide an appropriate substrate for B cell attachment. Thereby,
stromal cells for optimal B cell and B10 cell expansion would
minimally express CD154, BLyS, VCAM-1 and CD44, or other
functionally equivalent molecules, with exogenous IL-4 and IL-21
added or these cytokines produced by the stromal cells at optimized
levels.
[0172] Transfected stromal cell cultures that were functionally
selected for optimal CD154 and BLyS expression were able to support
B cell expansion, but there was tremendous heterogeneity between
different batch transfectants, individual clones, and their
subclones despite similar CD154 and BLyS expression. The tremendous
heterogeneity in abilities of different transfectants to support B
cell expansion was eventually explained by our finding that there
was extreme cellular and functional heterogeneity within each
CD154.sup.+ BLyS.sup.+ stromal cell population. Although
unexpected, it is well recognized that stromal cells can express
signaling molecules and secrete cytokines, can respond to some of
those signaling molecules and cytokines themselves, can respond to
exogenous cytokines added to the cultures, and that they can retain
differentiation potential depending on their culture
conditions.
[0173] Within our transfected stromal cell populations, we
determined that only a subset of the cells were able to support
robust B cell adhesion and clonal expansion, with a frequency that
was commonly <1% of stromal cells despite all of the cells
expressing CD154 and secreting BLyS. These stromal cell cultures
were generally able to induce B cell expansion by <20-fold.
However, mechanical isolation allowed us to isolate optimal cells
that uniformly supported B cell expansion over a broad range up to
25,000-fold as described above (FIG. 4). Stromal cells optimized
for maximal B cell and B10 cell growth can be mechanically isolated
based on phenotypic, morphologic and growth characteristics. For
example, it was possible to enrich for stromal cells that had a
greater capacity to support B cell expansion by isolating
individual stromal cells that supported B cell adhesion and rosette
formation. Additional mechanical means for isolating optimal
stromal cells for B cell expansion can include single cell-cloning
techniques, flow cytometry isolation of cells based on their
expression or loss of cell surface molecules, and/or other
techniques known to those with skill in the art, with the
subsequent functional identification of stromal cells that support
optimal B cell expansion.
[0174] The bone marrow microenvironment and stromal cells can
either positively or negatively influence whether a given B cell
precursor or B cell proliferates, differentiates, or undergoes
apoptosis. For example, several stromal cell lines that support
lymphocyte outgrowth suppress the spontaneous apoptosis of pre-B
cells by as much as 90%, while other stromal cell clones can induce
lymphocyte apoptosis, or can appear inert. Borghesi et al. 1997 J
Immunol 159:4171-4179. Similar observations have been made for the
stromal cells used for B cell expansion in our studies. As
examples, three representative clones expressing mouse CD154 and
human BLyS are shown with one transfected clone from 3T3-Balb/c
parental cells and two transfected clones (1 and 2) derived from
parental NIH-3T3 cells (Table 1). At the time of these studies,
clone #1 3T3-Balb/c cells supported optimal B cell expansion in
comparison with clones 1 and 2 of NIH-3T3 cell origin, which were
relatively less effective. Microarray analysis of these three
clones in comparison with their parental 3T3 cells demonstrated
considerable molecular heterogeneity between the cells cultured
under identical conditions. The expression of some molecules was
either upregulated or down-regulated, which correlated with optimal
B cell expansion. However, the level of molecular heterogeneity
between sub-clones was the most unexpected finding. Examples of the
molecular differences that are likely to be functional are
illustrated below.
[0175] Molecules that were upregulated in 3T3 cells with the
potential to significantly expand B cells included CD24, also known
as heat-stable antigen in the mouse. CD24 is a
glycosylphosphatidylinositol-anchored membrane protein of
heterogeneous molecular weight ranging from 30 to 70 kDa. The
mature protein is only 27 to 30 amino acids long, and most of the
molecular weight of the protein consists of extensive N- and
O-linked glycosylation. CD24 is expressed by B cells and their
precursors and neutrophils, in neuronal tissue, and in certain
epithelial cells. CD24 functions as a mucin-like adhesion molecule
that can facilitate and regulate cell-cell interactions. Increased
stromal cell IL-7 expression by clone #1 3T3-Balb/c cells may be
critical to B10 and B cell expansion. IL-7 is normally made at
extremely small levels by stromal cells, but it is an essential
stimulus for early B cell precursor replication, and other critical
developmental functions. Clone #1 3T3-Balb/c cells also expressed
Macrophage stimulating 1 (Mst1), also known as Ste20-like kinase or
STK4 (serine threonine kinase 4), the human ortholog of Drosophila
Hippo. STK4 is a central caspase 3-activated constituent of a
highly conserved pathway controlling cell growth and apoptosis.
Importantly, lymphocytes and neutrophils from STK4-deficient mice
exhibit enhanced loss of mitochondrial membrane potential and
increased susceptibility to apoptosis. Mst1 also has crucial roles
in lymphocyte adhesion to endothelial cells during lymphocyte
trafficking in vivo and Mst1.sup.-/- mice have hypotrophic
peripheral lymphoid tissues and reduced marginal zone B cells in
the spleen. Thymic stromal lymphopoietin (Tslp) protein is
primarily produced by certain stromal cells and fibroblasts and
acts on myeloid lineage cells to produce factors that influence T
cell lineage development and certain T cell subsets including
regulatory T cells. TSLP may also support B cell differentiation
from fetal hematopoietic progenitors. TSLP is proposed to signal
through a heterodimeric receptor complex composed of the TSLP
receptor and the IL-7Ra chain, suggesting that TSLP and IL-7 may
influence some signaling pathways in common.
[0176] Multiple stromal cell molecules are likely to negatively
influence B cell proliferation, differentiation, and interactions
with stromal cells, or induce their apoptosis. CD99 is expressed by
endothelial cells as well as most leukocytes, including B cells.
CD99 functions as an adhesion molecule, and also interacts with the
intracellular molecule cyclophylin A that is intricately involved
in inflammatory signaling pathways. Homotypic CD99-CD99
interactions have been shown between monocytes and endothelial
cells during diapedesis. CD99 signaling may be detrimental to B
cell expansion as CD99 ligation on early B cells using an anti-CD99
monoclonal antibody induces apoptosis. Likewise, CD99 signaling
induces the apoptosis of developing T cells in the thymus.
Interactions between the mouse homologue of CD99 (designated D4)
and its ligand, paired immunoglobulin-like type 2 receptor (PILR)
widely expressed by leukocytes, is a major mechanism inducing
thymocyte apoptosis.
[0177] As a second example, transforming growth factor beta-induced
(Tgfbi) expression was down-regulated by both clone #1 3T3-Balb/c
cells and clone #1 NIH-3T3 cells in comparison with their parental
cells. Transforming growth factor beta-induced (TGFBI) protein is a
secreted RGD-containing protein induced by transforming growth
factor-beta that binds to type I, II and IV collagens and may
thereby inhibit cell adhesion. RGD motifs are found in many
extracellular matrix proteins that modulate cell adhesion and the
motif serves as a ligand recognition sequence for several integrins
during cell-collagen interactions. TGFBI can inhibit adhesive
interactions regulating the invasive growth of melanoma cells. The
loss of TGFBI expression has been implicated in cell proliferation,
tumor progression, and angiogenesis.
[0178] In a third example, stromal cell CXCR7 transcripts were
down-regulated in both clone #1 3T3-Balb/c cells and clone #1
NIH-3T3 cells. CXCR7 (formerly RDC1) functions as a receptor for
the CXCL12 (formerly SDF-1) chemokine that binds B cells and can
regulate a spectrum of normal and pathological processes. CXCR7 can
function as a scavenger receptor for CXCL12 that is also normally
produced by both parental 3T3 cell lines. Thereby, stromal cell
loss of CXCR7 expression may facilitate CXCL12 binding to B cells
in the culture system.
[0179] Cell surface differentiation-regulating proteins may also be
counterproductive to optimal B cell expansion. Delta-like 1 and
Jagged 1 expression and their shared receptor Notch 1 were
down-regulated on clone #1 3T3-Balb/c cells in comparison with
untransfected parental cells. Notch, Delta-like and Jagged proteins
play pivotal roles in B cell development and activation. For
example, Notch-1 engagement on B cells by Delta-like 1 expressed on
stromal cells promotes B cell differentiation into
antibody-secreting cells, while Notch-1 interactions with Jagged-1
are inhibitory in this process. Also, Notch-Delta-like 1
interactions act in synergy with B cell antigen receptor and CD40
signaling to enhance B cell proliferation and isotype switching. In
addition, marginal zone B cell development critically requires
Delta-like 1 interactions with B cell-expressed Notch-2. Other
aspects of B cell development are negatively regulated by
Notch/Delta-like/Jagged interactions. For example, 3T3 fibroblasts
expressing Delta-like 1 have been reported to act as stromal cells
for adipocyte differentiation, but only support early B cell
differentiation when Delta-like expression is suppressed or if
interleukin-7 (IL-7) is also provided to the cultures. Therefore,
the role of the Notch/Delta-like/Jagged axis in the development and
function of B10 cells may be complex, but these proteins may be
critical regulators of B cell and B10 cell expansion.
[0180] Stromal cells for maximal B cell and B10 cell expansion may
thereby optimally express appropriate densities of CD154, BLyS,
VCAM-1 and CD44, or other functionally equivalent molecules, along
with optimal expression of some or all of the molecules outlined in
Table 1 in combination with exogenous IL-4 and IL-21 added to the
cultures. As each of the molecules that influence B cell and B10
cell expansion are better defined, it will be critical to evaluate
the function of each molecule in combination with other factors
endogenously expressed by the stromal cells and exogenous stimuli
added to the cultures. The cumulative effects of these positive and
negative regulators will also depend on the timing in which these
signals are presented during B cell and B10 cell expansion.
Thereby, a functional definition of optimal stromal cells for B
cell and B10 cell expansion is currently more operable than a
molecular definition that includes all factors and pathways that
are required to maximal B cell and B10 cell expansion.
TABLE-US-00001 TABLE 1 Transcripts expressed by stromal cells
optimized for B cell and B10 cell expansion. NIH 3T3-Swiss Gene
Fold- 3T3-Balb/c clone clone Par- Symbol Gene Title Change Clone 1
Parent 1 2 ent Relative ++++ - ++ + - capacity for B10 cell
expansion Upreg- ulated Cd24a CD24a antigen 10.13 3197 439 647 238
147 Cd24a CD24a antigen 6.05 5318 1317 1814 676 370 Cd24a CD24a
antigen 4.12 960 336 439 181 111 I17 interleukin 7 20.19 647 83 24
24 23 I17 interleukin 7 3.66 67 17 24 17 17 Mst1 macrophage 4.90
208 48 46 37 39 stimulating 1 Ts1p thymic stromal 1.23 82 20 355 74
38 lymphopoietin Downreg: Cd99 CD99 antigen -9.26 67 682 902 545
448 Cd99 CD99 antigen -9.43 65 631 892 529 481 Cd99 CD99 antigen
-22.14 35 899 1244 670 508 Cxcr7 chemokine -73.82 12 1684 55 2445
2543 (C-X-C motif) receptor 7 Dlk1 delta-like 1 -4.31 56 750 201
227 96 homolog (Drosophila) Dlk1 delta-like 1 -89.03 59 11502 8915
6262 1191 homolog (Drosophila) Jag1 jagged 1 -2.37 43 98 358 57 54
Jag1 jagged 1 -11.34 29 493 1755 103 128 Jag1 jagged 1 -53.26 18
2094 5614 149 434 Notch1 Notch gene -12.74 50 599 754 661 547
homolog 1 (Drosophila) Notch1 Notch gene -4.01 68 242 318 265 272
homolog 1 (Drosophila) Tgfbi transforming -14.43 13 192 19 586 570
growth factor, beta induced Tgfbi transforming -14.62 16 182 26 785
772 growth factor, beta induced Tgfbi transforming -36.28 11 539 11
2062 2196 growth factor, beta induced Tgfbi transforming -9.38 46
395 30 1815 1663 growth factor, beta induced Consti tutive: Cd44
CD44 antigen 1.30 416 688 123 308 403 Cd44 CD44 antigen -1.41 2061
5511 1508 2911 2937 Cd44 CD44 antigen -2.12 1826 5671 2410 4120
3991 Vcam1 vascular cell -1.94 193 326 1496 224 179 adhesion
molecule 1 Vcam1 vascular cell -2.16 132 347 778 152 162 adhesion
molecule 1 Vcam1 vascular cell -2.43 396 803 5015 545 388 adhesion
molecule 1 Vcam1 vascular cell -2.43 396 803 5015 545 388 adhesion
molecule 1 Total RNA was extracted from parental 3T3 cells and
their cDNA-transfected subclones using TRIzol (Invitrogen-Molecular
Probes), with relative transcript levels quantified in parallel by
GeneChip analysis (Affymetrix Mouse Genome 430 2.0 GeneChips;
Affymetrix, Santa Clara, CA). All quality parameters for the arrays
were confirmed to be in the range recommended by the manufacturer.
Linear relative expression levels are shown for each line. The
results for reiterative probes on each gene chip are shown.
Methods
[0181] Mice.
[0182] C57BL/6, IL-10.sup.-/- (B6.129P2-Il10.sup.tmlCgn/J) (Kuhn,
et al., Interleukin-10-deficient mice develop chronic
enterocolitis. Cell 75, 263-274 (1993)), CD40.sup.-/-
(B6.129P2-CD40.sup.tmlKik/J), and MD4 (C57BL/6-Tg(TghelMD4)4Ccg/J)
mice were from the Jackson Laboratory (Bar Harbor, Me.).
MHC-II.sup.-/- (B6.129-H2-Ab1.sup.tmlJaeB2m.sup.tmGruN17) mice
(Taconic Farms, Inc., Hudson, N.Y.) were as described (Grusby, M.
J. et al. Mice lacking major histocompatibility complex class I and
class II molecules. Proc. Natl. Acad. Sci. USA 90, 3913-3917
(1993)). CD19.sup.-/- mice were backcrossed onto the C57BL/6
background for 14 generations. See Sato, S., Ono, N., Steeber, D.
A., Pisetsky, D. S. & Tedder, T. F. CD19 regulates B lymphocyte
signaling thresholds critical for the development of B-1 lineage
cells and autoimmunity. J. Immunol. 157, 4371-4378 (1996) and Sato,
S., Steeber, D. A., Jansen, P. J. & Tedder, T. F. CD19
expression levels regulate B lymphocyte development: human CD19
restores normal function in mice lacking endogenous CD19. J.
Immunol. 158, 4662-4669 (1997). IL-21R.sup.-/- mice were as
described. See Ozaki, K. et al. A critical role for IL-21 in
regulating immunoglobulin production. Science 298, 1630-1634
(2002). TCR.sup.MOG transgenic mice ((Bettelli, E. et al. Myelin
oligodendrocyte glycoprotein-specific T cell receptor transgenic
mice develop spontaneous autoimmune optic neuritis. J. Exp. Med.
197, 1073-1081 (2003)) Thy1.2.sup.+, provided by Dr. V. K. Kuchroo,
Harvard Medical School, Boston, Mass.) were crossed to
C57BL/6.Thy1.1 mice to generate Thy1.1-expressing T cells. All mice
were bred in a specific pathogen-free barrier facility and used at
6-12 wks of age. The Duke University Animal Care and Use Committee
approved all studies.
[0183] Cell Preparation.
[0184] Single-cell suspensions from spleens and peripheral lymph
nodes (paired axillary and inguinal) were generated by gentle
dissection, with the cells passed through 70-mm cell strainers (BD
Biosciences, San Diego, Calif.) followed by percoll gradient
(70/37%) centrifugation. Lymphocytes were collected from the 37:70%
interface and washed. MACS (Miltenyi Biotech, Auburn, Calif.) was
used to purify lymphocyte populations according to the
manufacturer's instructions. CD19 mAb-coated microbeads and
CD4.sup.+ T cell isolation kits (Miltenyi Biotech) were used to
purify B cells and CD4.sup.+ T cells, respectively. When necessary,
the cells were enriched a second time using a fresh MACS column to
obtain >95% cell purities.
[0185] Immunofluorescence Analysis.
[0186] FITC-, PE-, PE-Cy5-, PE-Cy7-, or APC-conjugated CD1d (1B1),
CD4 (H129.19), CD5 (53-7.3), CD19 (1D3), B220 (RA3-6B2), and Thy1.1
(OX-7) mAbs were from BD Biosciences. PE-conjugated IL-21R (4A9)
mAb was from BioLegend (San Diego, Calif.). Intracellular staining
used mAbs reactive with IL-10 (JES5-16E3), IL-17 (17B7), and
IFN-.gamma. (XMG1.2) (all from eBioscience) and Cytofix/Cytoperm
kits (BD Biosciences). Background staining was assessed using
non-reactive, isotype-matched control mAbs (Caltag Laboratories,
San Francisco, Calif.). For two- to six-color immunofluorescence
analysis, single cell suspensions (10.sup.6 cells) were stained at
4.degree. C. using predetermined optimal mAb concentrations for 20
min as described. See Yanaba et al. 2008, Immunity 28, 639-650;
Matsushita et al. 2008, J. Clin. Invest. 118, 3420-3430; Matsushita
et al. 2010, J. Immunol. 185, 2240-2252; Matsushita and Tedder
2011, Methods Mol. Biol. 677, 99-111; and Zhou et al. 1994, Mol.
Cell. Biol. 14, 3884-3894. Blood erythrocytes were lysed after
staining using FACS.TM. Lysing Solution (Becton Dickinson, San
Jose, Calif.).
[0187] B cell intracellular IL-10 expression was visualized by
immunofluorescence staining and analyzed by flow cytometry as
described. See Yanaba et al. 2008, Immunity 28, 639-650 and
Matsushita and Tedder 2011, Methods Mol. Biol. 677, 99-111.
Briefly, isolated leukocytes or purified cells were resuspended
(2.times.10.sup.6 cells/ml) in complete medium (RPMI 1640 media
containing 10% FCS, 200 .mu.g/ml penicillin, 200 U/ml streptomycin,
4 mM L-Glutamine, and 5.times.10.sup.-5 M 2-mercaptoethanol, all
from Gibco, Carlsbad, Calif.) with LPS (10 .mu.g/ml, Escherichia
coli serotype 0111: B4, Sigma), PMA (50 ng/ml; Sigma), ionomycin
(500 ng/ml; Sigma) and monensin (2 .mu.M; eBioscience) for 5 h in
48-well flat-bottom plates. In some experiments, the cells were
incubated for 48 h with an agonistic anti-mouse CD40 mAb (1
.mu.g/ml; HM40-3 mAb; BD Pharmingen) as described. Yanaba et al.
2009, J. Immunol. 182, 7459-7472. For IL-10 detection, Fc receptors
were blocked with mouse Fc receptor mAb (2.4G2; BD PharMingen), and
dead cells were detected using a LIVE/DEAD.RTM. Fixable Violet Dead
Cell Stain Kit (Invitrogen-Molecular Probes) before cell surface
staining. Stained cells were fixed and permeabilized using a
Cytofix/Cytoperm kit (BD PharMingen) according to the
manufacturer's instructions and stained with PE-conjugated mouse
anti-IL-10 mAb. Splenocytes from IL-10.sup.-/- mice served as
negative controls to demonstrate specificity and to establish
background IL-10 staining levels. For T cell intracellular cytokine
staining, lymphocytes were stimulated in vitro with PMA (50 ng/ml;
Sigma, St. Louis, Mo.) and ionomycin (1 .mu.g/ml; Sigma) in the
presence of Brefeldin A (BFA, 1 .mu.l/ml; eBioscience) for 5 h
before staining. Viable cells with the forward and side light
scatter properties of lymphocytes were analyzed using a FACScan
flow cytometer (Becton Dickinson) or BD FACSCanto.TM. II (BD
Biosciences).
[0188] In Vitro B Cell Cultures.
[0189] Purified splenic B cells (1.times.10.sup.6/ml) were cultured
in RPMI 1640 medium containing 10% FBS, 2 mM L-Glutamine,
penicillin (100 I.U./ml), streptomycin (100 .mu.g/ml), and 50 .mu.M
2-mercapthoethanol, and either recombinant IFN-.gamma. (10
ng/ml.quadrature..quadrature. IL-4 (2 ng/ml), IL-6 (10 ng/ml) or
IL-21 (100 ng/ml) (from e-Bioscience); TGF-.beta. (10 ng/ml), IL-10
(10 ng/ml), or IL-12 (10 ng/ml) (from R&D systems, Minneapolis,
Minn.); or IL-23 (20 ng/ml) and IL-27 (100 ng/ml) (Biolegend), or
LPS (10 .mu.g/ml) before B10 cell numbers and culture supernatant
fluid IL-10 concentrations were determined. IL-10 concentrations
were determined by ELISA. In separate experiments, purified spleen
B cells were cultured with NIH-3T3 cells expressing CD154 and BLyS
as described with exogenous recombinant IL-4 (2 ng/ml) or IL-21 (10
ng/ml) added to the cultures. Nojima et al. 2011, Nature Comm. 2,
465 and Tedder et al. in Leukocyte Typing V: White Cell
Differentiation Antigens. Vol. 1 (eds S. F. Schlossman et al.)
483-504 (Oxford University Press, 1995). For adoptive transfer
experiments, cultured CD5.sup.+ and CD5.sup.- B cells were purified
by cell sorting (FACSVantage SE, Becton Dickinson), with purities
of 95-98%. After purification, 1.times.10.sup.6 cells were
immediately transferred i.v. into each recipient mouse. In some
experiments, CD40 mAb (clone HM40-3; hamster, no
azide/endotoxin-free, BD Pharmingen, San Jose, Calif.) was added to
cultures where indicated.
[0190] EAE Induction.
[0191] EAE was induced in 6- to 8-week-old female mice by
subcutaneous immunization with 100 .mu.g of MOG.sub.35-55 peptide
(MEVGWYRSPFSRVVHLYRNGK; NeoMPS, San Diego, Calif.) emulsified in
CFA containing 200 .mu.g of heat-killed Mycobacterium tuberculosis
H37RA (Difco, Detroit, Mich.) on day 0. See Matsushita et al. 2008,
J. Clin. Invest. 118, 3420-3430 and Matsushita et al. 2010, J.
Immunol. 185, 2240-2252. Additionally, mice received 200 ng of
pertussis toxin (List Biological Laboratories, Campbell, Calif.)
i.p. in 0.5 ml of PBS on days 0 and 2. Clinical signs of disease
were assessed daily with a 0 to 6 point scoring system: 0, normal;
1, flaccid tail; 2, impaired righting reflex and/or gait; 3,
partial hind limb paralysis; 4, total hind limb paralysis; 5, hind
limb paralysis with partial forelimb paralysis; 6, moribund state,
as described. Fillatreau et al. 2002, Nat. Immunol. 3, 944-950.
Moribund mice were given disease severity scores of 6 and
euthanized.
[0192] Adoptive Transfer Experiments.
[0193] B cells from naive mice or mice with EAE (day 28) were first
enriched using CD19 mAb-coated microbeads, stained for cell surface
CD19, CD1d and CD5 expression, with CD1d.sup.hiCD5.sup.+ and
CD1d.sup.loCD5.sup.- B cells purified by cell sorting as described
with purities of 95-98%. See Matsushita 2011, Methods Mol. Biol.
677, 99-111 and Yanaba et al. 2008, Immunity 28, 639-650. After
purification, the CD1d.sup.hiCD5.sup.+ or CD1d.sup.loCD5.sup.- B
cells (1.times.10.sup.6) were immediately transferred i.v. into
recipient mice, with B10 cells representing 13-20% and <0.1% of
the transferred cells. In some experiments, donor Thy1.1 CD4.sup.+
T cells were isolated from pooled spleens and lymph nodes of
TCR.sup.MOG transgenic mice, then labeled with CFSE Vybrant.TM.
CFDA SE fluorescent dye (5 .mu.M; CFSE; Invitrogen) and transferred
i.v. (5.times.10.sup.6/mouse) into Thy1.2 congenic recipients. Five
days after adoptive transfer, the TCR.sup.MOG CD4.sup.+ T cells
were assessed by flow cytometry.
[0194] Statistical Analysis.
[0195] All data are shown as means (.+-.SEM). The significance of
differences between sample means was determined using the Student's
t test.
* * * * *